CA3006073A1 - Topical veterinary formulations comprising fipronil and methoprene - Google Patents
Topical veterinary formulations comprising fipronil and methoprene Download PDFInfo
- Publication number
- CA3006073A1 CA3006073A1 CA3006073A CA3006073A CA3006073A1 CA 3006073 A1 CA3006073 A1 CA 3006073A1 CA 3006073 A CA3006073 A CA 3006073A CA 3006073 A CA3006073 A CA 3006073A CA 3006073 A1 CA3006073 A1 CA 3006073A1
- Authority
- CA
- Canada
- Prior art keywords
- topical formulation
- formulation according
- fipronil
- pyriproxyfen
- methoprene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 198
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 title claims abstract description 156
- 239000005899 Fipronil Substances 0.000 title claims abstract description 149
- 229940013764 fipronil Drugs 0.000 title claims abstract description 149
- 238000009472 formulation Methods 0.000 title claims abstract description 125
- 230000000699 topical effect Effects 0.000 title claims abstract description 17
- 229930002897 methoprene Natural products 0.000 title claims description 33
- 229950003442 methoprene Drugs 0.000 title claims description 33
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 title claims description 29
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 205
- 241001465754 Metazoa Species 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 29
- 244000078703 ectoparasite Species 0.000 claims abstract description 28
- 206010061217 Infestation Diseases 0.000 claims abstract description 12
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 108
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 108
- 239000005927 Pyriproxyfen Substances 0.000 claims description 65
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 claims description 65
- -1 sorbitan ester Chemical class 0.000 claims description 63
- 239000003963 antioxidant agent Substances 0.000 claims description 54
- 235000006708 antioxidants Nutrition 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000003112 inhibitor Substances 0.000 claims description 48
- 238000002425 crystallisation Methods 0.000 claims description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 239000003960 organic solvent Substances 0.000 claims description 39
- NFGXHKASABOEEW-MRXNPFEDSA-N (S)-methoprene Chemical compound COC(C)(C)CCC[C@H](C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-MRXNPFEDSA-N 0.000 claims description 37
- 229930012896 (S)-methoprene Natural products 0.000 claims description 37
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 35
- 239000013543 active substance Substances 0.000 claims description 34
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 32
- 239000004544 spot-on Substances 0.000 claims description 32
- 239000006184 cosolvent Substances 0.000 claims description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 27
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 27
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 27
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000009835 boiling Methods 0.000 claims description 22
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims description 18
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 18
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- 239000003093 cationic surfactant Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 claims description 9
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 claims description 9
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 9
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 claims description 9
- 229930195733 hydrocarbon Natural products 0.000 claims description 9
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- WMDZKDKPYCNCDZ-UHFFFAOYSA-N 2-(2-butoxypropoxy)propan-1-ol Chemical compound CCCCOC(C)COC(C)CO WMDZKDKPYCNCDZ-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000002280 amphoteric surfactant Substances 0.000 claims description 8
- 239000003945 anionic surfactant Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000002736 nonionic surfactant Substances 0.000 claims description 8
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 claims description 6
- LVUQCTGSDJLWCE-UHFFFAOYSA-N 1-benzylpyrrolidin-2-one Chemical compound O=C1CCCN1CC1=CC=CC=C1 LVUQCTGSDJLWCE-UHFFFAOYSA-N 0.000 claims description 6
- ZDOOQPFIGYHZFV-UHFFFAOYSA-N 2-ethyl-4-[(4-phenoxyphenoxy)methyl]-1,3-dioxolane Chemical compound O1C(CC)OCC1COC(C=C1)=CC=C1OC1=CC=CC=C1 ZDOOQPFIGYHZFV-UHFFFAOYSA-N 0.000 claims description 6
- 239000005878 Azadirachtin Substances 0.000 claims description 6
- 239000005891 Cyromazine Substances 0.000 claims description 6
- 239000005898 Fenoxycarb Substances 0.000 claims description 6
- 239000005912 Lufenuron Substances 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- VEHPJKVTJQSSKL-UHFFFAOYSA-N azadirachtin Natural products O1C2(C)C(C3(C=COC3O3)O)CC3C21C1(C)C(O)C(OCC2(OC(C)=O)C(CC3OC(=O)C(C)=CC)OC(C)=O)C2C32COC(C(=O)OC)(O)C12 VEHPJKVTJQSSKL-UHFFFAOYSA-N 0.000 claims description 6
- FTNJWQUOZFUQQJ-NDAWSKJSSA-N azadirachtin A Chemical compound C([C@@H]([C@]1(C=CO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@]1(C)[C@H](O)[C@H](OC[C@@]2([C@@H](C[C@@H]3OC(=O)C(\C)=C\C)OC(C)=O)C(=O)OC)[C@@H]2[C@]32CO[C@@](C(=O)OC)(O)[C@@H]12 FTNJWQUOZFUQQJ-NDAWSKJSSA-N 0.000 claims description 6
- FTNJWQUOZFUQQJ-IRYYUVNJSA-N azadirachtin A Natural products C([C@@H]([C@]1(C=CO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@]1(C)[C@H](O)[C@H](OC[C@@]2([C@@H](C[C@@H]3OC(=O)C(\C)=C/C)OC(C)=O)C(=O)OC)[C@@H]2[C@]32CO[C@@](C(=O)OC)(O)[C@@H]12 FTNJWQUOZFUQQJ-IRYYUVNJSA-N 0.000 claims description 6
- 229950000775 cyromazine Drugs 0.000 claims description 6
- LVQDKIWDGQRHTE-UHFFFAOYSA-N cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 claims description 6
- APMCZEMFQVQTHY-AGACNZRVSA-N dimethyl (1S,4S,5R,6S,7S,8R,11S,12R,14S,15R)-12-acetyloxy-4,7-dihydroxy-6-[(1S,2S,6S,8S,9R,11S)-2-hydroxy-11-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,11]dodecan-9-yl]-6-methyl-14-(2-methylbutanoyloxy)-3,9-dioxatetracyclo[6.6.1.01,5.011,15]pentadecane-4,11-dicarboxylate Chemical compound C([C@@H]([C@]1(CCO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@](C)([C@@H]1O)[C@@H]2[C@@](O)(C(=O)OC)OC[C@@]32[C@H]2[C@H]1OC[C@]2(C(=O)OC)[C@H](OC(C)=O)C[C@@H]3OC(=O)C(C)CC APMCZEMFQVQTHY-AGACNZRVSA-N 0.000 claims description 6
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 claims description 6
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 claims description 6
- 229930000073 hydroprene Natural products 0.000 claims description 6
- 229930001540 kinoprene Natural products 0.000 claims description 6
- 229960000521 lufenuron Drugs 0.000 claims description 6
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000003403 methoprene group Chemical group 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 claims description 3
- QKGBRANQIWBMED-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrolidin-2-one Chemical compound COCCN1CCCC1=O QKGBRANQIWBMED-UHFFFAOYSA-N 0.000 claims description 3
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 claims description 3
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 claims description 3
- BAWUFGWWCWMUNU-UHFFFAOYSA-N 1-hexylpyrrolidin-2-one Chemical compound CCCCCCN1CCCC1=O BAWUFGWWCWMUNU-UHFFFAOYSA-N 0.000 claims description 3
- GHELJWBGTIKZQW-UHFFFAOYSA-N 1-propan-2-ylpyrrolidin-2-one Chemical compound CC(C)N1CCCC1=O GHELJWBGTIKZQW-UHFFFAOYSA-N 0.000 claims description 3
- WPPOGHDFAVQKLN-UHFFFAOYSA-N N-Octyl-2-pyrrolidone Chemical compound CCCCCCCCN1CCCC1=O WPPOGHDFAVQKLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004133 Sodium thiosulphate Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- PZYDAVFRVJXFHS-UHFFFAOYSA-N n-cyclohexyl-2-pyrrolidone Chemical compound O=C1CCCN1C1CCCCC1 PZYDAVFRVJXFHS-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 239000004296 sodium metabisulphite Substances 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 241000238876 Acari Species 0.000 abstract description 19
- 244000045947 parasite Species 0.000 abstract description 15
- 241000238631 Hexapoda Species 0.000 abstract description 8
- 239000003630 growth substance Substances 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical compound C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 42
- 241000282472 Canis lupus familiaris Species 0.000 description 30
- 235000013601 eggs Nutrition 0.000 description 25
- 241000258242 Siphonaptera Species 0.000 description 22
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 18
- 229920000053 polysorbate 80 Polymers 0.000 description 18
- 229940068968 polysorbate 80 Drugs 0.000 description 18
- 239000005660 Abamectin Substances 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 150000003839 salts Chemical group 0.000 description 16
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 13
- 241000255925 Diptera Species 0.000 description 12
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Chemical class COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 229930185156 spinosyn Natural products 0.000 description 9
- 241000258922 Ctenocephalides Species 0.000 description 8
- 241001481703 Rhipicephalus <genus> Species 0.000 description 8
- 239000002949 juvenile hormone Substances 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 6
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001674048 Phthiraptera Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960002418 ivermectin Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 5
- 241000920471 Lucilia caesar Species 0.000 description 5
- 208000006123 Myiasis Diseases 0.000 description 5
- 229950008167 abamectin Drugs 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- 239000004540 pour-on Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241001480824 Dermacentor Species 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241000257232 Haematobia irritans Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 241000509416 Sarcoptes Species 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 230000002506 adulticidal effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 4
- 229960003997 doramectin Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000032669 eclosion Effects 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 125000004961 1-arylpyrazolyl group Chemical group 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010002156 Depsipeptides Proteins 0.000 description 3
- 239000005894 Emamectin Substances 0.000 description 3
- 241001113970 Linognathus Species 0.000 description 3
- 239000005918 Milbemectin Substances 0.000 description 3
- 241000790250 Otodectes Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000238680 Rhipicephalus microplus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001259047 Trichodectes Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 description 3
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 3
- 229960002346 eprinomectin Drugs 0.000 description 3
- 229950000961 latidectin Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 3
- 229940099245 milbemycin oxime Drugs 0.000 description 3
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 3
- 229960004816 moxidectin Drugs 0.000 description 3
- UVZZDDLIOJPDKX-ITKQZBBDSA-N paraherquamide Chemical class O1C(C)(C)C=COC2=C1C=CC1=C2NC(=O)[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 UVZZDDLIOJPDKX-ITKQZBBDSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 3
- 229960002245 selamectin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- CFRPSFYHXJZSBI-DHZHZOJOSA-N (E)-nitenpyram Chemical compound [O-][N+](=O)/C=C(\NC)N(CC)CC1=CC=C(Cl)N=C1 CFRPSFYHXJZSBI-DHZHZOJOSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 description 2
- LUVQSCCABURXJL-UHFFFAOYSA-N 1-tert-butylpyrrolidin-2-one Chemical compound CC(C)(C)N1CCCC1=O LUVQSCCABURXJL-UHFFFAOYSA-N 0.000 description 2
- UNCVXXVJJXJZII-QLETUHIQSA-N 1k1cu6363a Chemical compound OC(=O)C(/C)=C/C=C/[C@@](C)([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@]1(C)[C@@H]2CC2=C1N1[C@@H](C(=C)C)C(=O)C3=C([C@@H](O)[C@@H]4C(OC(C)(C)C=C44)(C)C)C4=CC2=C31 UNCVXXVJJXJZII-QLETUHIQSA-N 0.000 description 2
- KXPXKNBDCUOENF-UHFFFAOYSA-N 2-(Octylthio)ethanol Chemical compound CCCCCCCCSCCO KXPXKNBDCUOENF-UHFFFAOYSA-N 0.000 description 2
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 2
- XNYGOEGATLFFOX-UHFFFAOYSA-N 4,5a,6,9,9a,9b-hexahydro-1h-dibenzofuran-4a-carbaldehyde Chemical compound C12CC=CCC2OC2(C=O)C1CC=CC2 XNYGOEGATLFFOX-UHFFFAOYSA-N 0.000 description 2
- 241000256111 Aedes <genus> Species 0.000 description 2
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- JFLRKDZMHNBDQS-UCQUSYKYSA-N CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C Chemical compound CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C JFLRKDZMHNBDQS-UCQUSYKYSA-N 0.000 description 2
- 241000258924 Ctenocephalides felis Species 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 241001128004 Demodex Species 0.000 description 2
- 241000202828 Dermatobia hominis Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000005893 Diflubenzuron Substances 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 208000006004 Flea Infestations Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 241000257166 Lucilia cuprina Species 0.000 description 2
- 241000736227 Lucilia sericata Species 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 229930188848 Marcfortine Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000403354 Microplus Species 0.000 description 2
- BWCRYQGQPDBOAU-UHFFFAOYSA-N Milbemycin D Natural products C1CC(C)C(C(C)C)OC21OC(CC=C(C)CC(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 BWCRYQGQPDBOAU-UHFFFAOYSA-N 0.000 description 2
- 241000257229 Musca <genus> Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241001649230 Psoroptes ovis Species 0.000 description 2
- 241000718000 Pulex irritans Species 0.000 description 2
- 239000005929 Spinetoram Substances 0.000 description 2
- GOENIMGKWNZVDA-OAMCMWGQSA-N Spinetoram Chemical compound CO[C@@H]1[C@H](OCC)[C@@H](OC)[C@H](C)O[C@H]1OC1C[C@H]2[C@@H]3C=C4C(=O)[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@H](CC5)N(C)C)CCC[C@H](CC)OC(=O)CC4[C@@H]3CC[C@@H]2C1 GOENIMGKWNZVDA-OAMCMWGQSA-N 0.000 description 2
- 239000005930 Spinosad Substances 0.000 description 2
- 241001494139 Stomoxys Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 230000000895 acaricidal effect Effects 0.000 description 2
- 239000000642 acaricide Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008361 aminoacetonitriles Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 239000003717 antitrematodal agent Substances 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940019503 diflubenzuron Drugs 0.000 description 2
- QQQYTWIFVNKMRW-UHFFFAOYSA-N diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 2
- CMZOLQQGUABKKN-STGYROPVSA-N dimadectin Chemical compound O([C@H]1C[C@@H](C2)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@H](C)[C@@H](C(=C/C1)\C)OCOCCOC)[C@]12CC[C@H](C)[C@@H](C(C)C)O1 CMZOLQQGUABKKN-STGYROPVSA-N 0.000 description 2
- 229950004439 dimadectin Drugs 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010056417 emodepside Proteins 0.000 description 2
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical compound C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 description 2
- 229960001575 emodepside Drugs 0.000 description 2
- 244000079386 endoparasite Species 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- HICUREFSAIZXFQ-JOWPUVSESA-N i9z29i000j Chemical compound C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\[C@H](OC(=O)C(=N/OC)\C=1C=CC=CC=1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 HICUREFSAIZXFQ-JOWPUVSESA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 229930014550 juvenile hormone Natural products 0.000 description 2
- 150000003633 juvenile hormone derivatives Chemical class 0.000 description 2
- 229930191400 juvenile hormones Natural products 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VOZIAWLUULBIPN-LRBNAKOISA-N milbemycin A4 Chemical compound C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 VOZIAWLUULBIPN-LRBNAKOISA-N 0.000 description 2
- BWCRYQGQPDBOAU-WZBVPYLGSA-N milbemycin D Chemical compound C1C[C@H](C)[C@@H](C(C)C)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 BWCRYQGQPDBOAU-WZBVPYLGSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WTERNLDOAPYGJD-SFHVURJKSA-N monepantel Chemical compound C([C@@](C)(NC(=O)C=1C=CC(SC(F)(F)F)=CC=1)C#N)OC1=CC(C#N)=CC=C1C(F)(F)F WTERNLDOAPYGJD-SFHVURJKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- YNFMRVVYUVPIAN-AQUURSMBSA-N nemadectin Chemical compound C1[C@H](O)[C@H](C)[C@@H](C(/C)=C/C(C)C)O[C@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YNFMRVVYUVPIAN-AQUURSMBSA-N 0.000 description 2
- 229950009729 nemadectin Drugs 0.000 description 2
- YNFMRVVYUVPIAN-UHFFFAOYSA-N nemadectin alpha Natural products C1C(O)C(C)C(C(C)=CC(C)C)OC11OC(CC=C(C)CC(C)C=CC=C2C3(C(C(=O)O4)C=C(C)C(O)C3OC2)O)CC4C1 YNFMRVVYUVPIAN-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940079888 nitenpyram Drugs 0.000 description 2
- SGKGVABHDAQAJO-UHFFFAOYSA-N nitroxynil Chemical compound OC1=C(I)C=C(C#N)C=C1[N+]([O-])=O SGKGVABHDAQAJO-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- 229960001914 paromomycin Drugs 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229940014213 spinosad Drugs 0.000 description 2
- SRJQTHAZUNRMPR-UYQKXTDMSA-N spinosyn A Chemical compound O([C@H]1CCC[C@@H](OC(=O)C[C@H]2[C@@H]3C=C[C@@H]4C[C@H](C[C@H]4[C@@H]3C=C2C(=O)[C@@H]1C)O[C@H]1[C@@H]([C@H](OC)[C@@H](OC)[C@H](C)O1)OC)CC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 SRJQTHAZUNRMPR-UYQKXTDMSA-N 0.000 description 2
- SRJQTHAZUNRMPR-UHFFFAOYSA-N spinosyn A Natural products CC1C(=O)C2=CC3C4CC(OC5C(C(OC)C(OC)C(C)O5)OC)CC4C=CC3C2CC(=O)OC(CC)CCCC1OC1CCC(N(C)C)C(C)O1 SRJQTHAZUNRMPR-UHFFFAOYSA-N 0.000 description 2
- RDECBWLKMPEKPM-PSCJHHPTSA-N spinosyn D Chemical compound O([C@H]1CCC[C@@H](OC(=O)C[C@H]2[C@@H]3C=C(C)[C@@H]4C[C@H](C[C@H]4[C@@H]3C=C2C(=O)[C@@H]1C)O[C@H]1[C@@H]([C@H](OC)[C@@H](OC)[C@H](C)O1)OC)CC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 RDECBWLKMPEKPM-PSCJHHPTSA-N 0.000 description 2
- RDECBWLKMPEKPM-UHFFFAOYSA-N spinosyn D Natural products CC1C(=O)C2=CC3C4CC(OC5C(C(OC)C(OC)C(C)O5)OC)CC4C(C)=CC3C2CC(=O)OC(CC)CCCC1OC1CCC(N(C)C)C(C)O1 RDECBWLKMPEKPM-UHFFFAOYSA-N 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 2
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZCVAOQKBXKSDMS-AQYZNVCMSA-N (+)-trans-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-AQYZNVCMSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SBNFWQZLDJGRLK-RTWAWAEBSA-N (1R)-trans-phenothrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-RTWAWAEBSA-N 0.000 description 1
- DAASOABUJRMZAD-NRYKZSQYSA-N (1R,4S,5S)-5-(bromomethyl)-1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene Chemical compound BrC[C@H]1C[C@@]2(Cl)C(Cl)=C(Cl)[C@]1(Cl)C2(Cl)Cl DAASOABUJRMZAD-NRYKZSQYSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- PCKNFPQPGUWFHO-SXBRIOAWSA-N (Z)-flucycloxuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1)=CC=C1CO\N=C(C=1C=CC(Cl)=CC=1)\C1CC1 PCKNFPQPGUWFHO-SXBRIOAWSA-N 0.000 description 1
- IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical compound C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- FLEFKKUZMDEUIP-QFIPXVFZSA-N 1-[6-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-QFIPXVFZSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- BNXZHVUCNYMNOS-UHFFFAOYSA-N 1-butylpyrrolidin-2-one Chemical compound CCCCN1CCCC1=O BNXZHVUCNYMNOS-UHFFFAOYSA-N 0.000 description 1
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 description 1
- FMTFEIJHMMQUJI-NJAFHUGGSA-N 102130-98-3 Natural products CC=CCC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]1[C@@H](C=C(C)C)C1(C)C FMTFEIJHMMQUJI-NJAFHUGGSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- RPAJWWXZIQJVJF-UHFFFAOYSA-N 2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfinylphenol Chemical compound OC1=C(Cl)C=C(Cl)C=C1S(=O)C1=CC(Cl)=CC(Cl)=C1O RPAJWWXZIQJVJF-UHFFFAOYSA-N 0.000 description 1
- CZGIRAWWWHPJHM-UHFFFAOYSA-N 2-(3-methylpent-1-yn-3-yloxycarbonyl)benzoic acid Chemical compound CCC(C)(C#C)OC(=O)C1=CC=CC=C1C(O)=O CZGIRAWWWHPJHM-UHFFFAOYSA-N 0.000 description 1
- IKUGNXPCGVYRHO-UHFFFAOYSA-M 2-[2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-n,n,1-trimethylquinolin-1-ium-6-amine;chloride Chemical compound [Cl-].C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1\C=C\C(=C1C)C=C(C)N1C1=CC=CC=C1 IKUGNXPCGVYRHO-UHFFFAOYSA-M 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- YWDWYOALXURQPZ-CYBMUJFWSA-N 2-methyl-n-[3-[(6s)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl]phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC=CC([C@@H]2N=C3SCCN3C2)=C1 YWDWYOALXURQPZ-CYBMUJFWSA-N 0.000 description 1
- SWDPECKACXBPCX-UHFFFAOYSA-N 3,3,3-tris(4-chlorophenyl)-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C)CCN1C(=O)CC(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 SWDPECKACXBPCX-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OXDDDHGGRFRLEE-UHFFFAOYSA-N 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)NCC(=O)NCC(F)(F)F)=CC=C1C(C1)=NOC1(C(F)(F)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 OXDDDHGGRFRLEE-UHFFFAOYSA-N 0.000 description 1
- QOVTVIYTBRHADL-UHFFFAOYSA-N 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide Chemical compound NC1=CC(C(Cl)=C(Cl)Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O QOVTVIYTBRHADL-UHFFFAOYSA-N 0.000 description 1
- QMAHSUSUOMSSBK-UHFFFAOYSA-M 4-chlorobenzenesulfonate;dimethyl-(2-phenoxyethyl)-(thiophen-2-ylmethyl)azanium Chemical compound [O-]S(=O)(=O)C1=CC=C(Cl)C=C1.C=1C=CSC=1C[N+](C)(C)CCOC1=CC=CC=C1 QMAHSUSUOMSSBK-UHFFFAOYSA-M 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- NYQDCVLCJXRDSK-UHFFFAOYSA-N Bromofos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(Br)C=C1Cl NYQDCVLCJXRDSK-UHFFFAOYSA-N 0.000 description 1
- KWGUFOITWDSNQY-UHFFFAOYSA-N Bromophos-ethyl Chemical group CCOP(=S)(OCC)OC1=CC(Cl)=C(Br)C=C1Cl KWGUFOITWDSNQY-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- VEDTXTNSFWUXGQ-UHFFFAOYSA-N Carbophenothion Chemical compound CCOP(=S)(OCC)SCSC1=CC=C(Cl)C=C1 VEDTXTNSFWUXGQ-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000005944 Chlorpyrifos Substances 0.000 description 1
- 241000359266 Chorioptes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000933851 Cochliomyia Species 0.000 description 1
- 241000202814 Cochliomyia hominivorax Species 0.000 description 1
- XXXSILNSXNPGKG-ZHACJKMWSA-N Crotoxyphos Chemical compound COP(=O)(OC)O\C(C)=C\C(=O)OC(C)C1=CC=CC=C1 XXXSILNSXNPGKG-ZHACJKMWSA-N 0.000 description 1
- 241000490513 Ctenocephalides canis Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 239000005946 Cypermethrin Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 241000268912 Damalinia Species 0.000 description 1
- 239000005892 Deltamethrin Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- VBKKVDGJXVOLNE-UHFFFAOYSA-N Dioxation Chemical compound CCOP(=S)(OCC)SC1OCCOC1SP(=S)(OCC)OCC VBKKVDGJXVOLNE-UHFFFAOYSA-N 0.000 description 1
- 241000935792 Dipylidium caninum Species 0.000 description 1
- UVGTXNPVQOQFQW-UHFFFAOYSA-N Disophenol Chemical compound OC1=C(I)C=C([N+]([O-])=O)C=C1I UVGTXNPVQOQFQW-UHFFFAOYSA-N 0.000 description 1
- 206010014143 Ectoparasitic Infestations Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 description 1
- 241000322646 Felicola Species 0.000 description 1
- JHJOOSLFWRRSGU-UHFFFAOYSA-N Fenchlorphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl JHJOOSLFWRRSGU-UHFFFAOYSA-N 0.000 description 1
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CEAGUSGLAUVBEQ-UHFFFAOYSA-N Forosamine Natural products CC1CC(N(C)C)CC(O)O1 CEAGUSGLAUVBEQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000027582 GPCRs class B Human genes 0.000 description 1
- 108091008883 GPCRs class B Proteins 0.000 description 1
- 241001480796 Haemaphysalis Species 0.000 description 1
- 241000790933 Haematopinus Species 0.000 description 1
- 101000834981 Homo sapiens Testis, prostate and placenta-expressed protein Proteins 0.000 description 1
- 241001480803 Hyalomma Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 241000257176 Hypoderma <fly> Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005906 Imidacloprid Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 239000012565 Kollidon 17 Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 239000005914 Metaflumizone Substances 0.000 description 1
- MIFOMMKAVSCNKQ-HWIUFGAZSA-N Metaflumizone Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)N\N=C(C=1C=C(C=CC=1)C(F)(F)F)\CC1=CC=C(C#N)C=C1 MIFOMMKAVSCNKQ-HWIUFGAZSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QRBVCAWHUSTDOT-UHFFFAOYSA-N Methyridine Chemical compound COCCC1=CC=CC=N1 QRBVCAWHUSTDOT-UHFFFAOYSA-N 0.000 description 1
- PYCSFZRHAYWHQB-UHFFFAOYSA-N Mirasan Chemical compound CCN(CC)CCNC1=CC=C(C)C(Cl)=C1 PYCSFZRHAYWHQB-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 description 1
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 description 1
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 description 1
- SBKMRXDBQFVGJW-UHFFFAOYSA-N NC(=O)NC1=CC=C(OC(F)(F)C(F)F)C=C1F Chemical compound NC(=O)NC1=CC=C(OC(F)(F)C(F)F)C=C1F SBKMRXDBQFVGJW-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 description 1
- 241001036422 Nosopsyllus fasciatus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108010004210 PF 1022A Proteins 0.000 description 1
- YJNUXGPXJFAUQJ-LYWANRAQSA-N PF1022A Chemical compound C([C@@H]1C(=O)N(C)[C@H](C(O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C1=CC=CC=C1 YJNUXGPXJFAUQJ-LYWANRAQSA-N 0.000 description 1
- 239000005921 Phosmet Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004659 Presynaptic Receptors Human genes 0.000 description 1
- 108010003717 Presynaptic Receptors Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241001649229 Psoroptes Species 0.000 description 1
- OOPDAHSJBRZRPH-UHFFFAOYSA-L Pyrvinium pamoate Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C12=CC=CC=C2C=C(C([O-])=O)C(O)=C1CC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 OOPDAHSJBRZRPH-UHFFFAOYSA-L 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 241000187560 Saccharopolyspora Species 0.000 description 1
- 241000868102 Saccharopolyspora spinosa Species 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- IHGXGNJRCONUAC-WNTSOVQUSA-N Spinosyn J Chemical compound O([C@H]1CCC[C@@H](OC(=O)C[C@H]2[C@@H]3C=C[C@@H]4C[C@H](C[C@H]4[C@@H]3C=C2C(=O)[C@@H]1C)O[C@H]1[C@@H]([C@H](O)[C@@H](OC)[C@H](C)O1)OC)CC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 IHGXGNJRCONUAC-WNTSOVQUSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
- 239000005937 Tebufenozide Substances 0.000 description 1
- 239000005938 Teflubenzuron Substances 0.000 description 1
- 102100026164 Testis, prostate and placenta-expressed protein Human genes 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- CRPUJAZIXJMDBK-UHFFFAOYSA-N Toxaphene Natural products C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 1
- 239000005942 Triflumuron Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 241000353223 Xenopsylla cheopis Species 0.000 description 1
- GBAWQJNHVWMTLU-RQJHMYQMSA-N [(1R,5S)-7-chloro-6-bicyclo[3.2.0]hepta-2,6-dienyl] dimethyl phosphate Chemical compound C1=CC[C@@H]2C(OP(=O)(OC)OC)=C(Cl)[C@@H]21 GBAWQJNHVWMTLU-RQJHMYQMSA-N 0.000 description 1
- IXEVGHXRXDBAOB-GBIKHYSHSA-N [(1r,3s,4s)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-thiocyanatoacetate Chemical compound C1C[C@]2(C)[C@@H](OC(=O)CSC#N)C[C@@H]1C2(C)C IXEVGHXRXDBAOB-GBIKHYSHSA-N 0.000 description 1
- VXSIXFKKSNGRRO-MXOVTSAMSA-N [(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate;[(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-3-[(e)-3-methoxy-2-methyl-3-oxoprop-1-enyl Chemical class CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1.CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VXSIXFKKSNGRRO-MXOVTSAMSA-N 0.000 description 1
- FSAVDKDHPDSCTO-WQLSENKSSA-N [(z)-2-chloro-1-(2,4-dichlorophenyl)ethenyl] diethyl phosphate Chemical compound CCOP(=O)(OCC)O\C(=C/Cl)C1=CC=C(Cl)C=C1Cl FSAVDKDHPDSCTO-WQLSENKSSA-N 0.000 description 1
- ICKMASVVMCGZLR-UHFFFAOYSA-N [2-[(4-chlorophenyl)carbamoyl]-4,6-diiodophenyl] acetate Chemical compound CC(=O)OC1=C(I)C=C(I)C=C1C(=O)NC1=CC=C(Cl)C=C1 ICKMASVVMCGZLR-UHFFFAOYSA-N 0.000 description 1
- NRFGEDASJHBPPN-UHFFFAOYSA-N [2-bromo-6-[(4-bromophenyl)carbamothioyl]-4-chlorophenyl] acetate Chemical compound CC(=O)OC1=C(Br)C=C(Cl)C=C1C(=S)NC1=CC=C(Br)C=C1 NRFGEDASJHBPPN-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000982 afoxolaner Drugs 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940024113 allethrin Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- XJHDMGJURBVLLE-BOCCBSBMSA-N alpha-santonin Chemical compound C([C@]1(C)CC2)=CC(=O)C(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 XJHDMGJURBVLLE-BOCCBSBMSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 229950008286 amoscanate Drugs 0.000 description 1
- DKVNAGXPRSYHLB-UHFFFAOYSA-N amoscanate Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=CC=C(N=C=S)C=C1 DKVNAGXPRSYHLB-UHFFFAOYSA-N 0.000 description 1
- 244000000054 animal parasite Species 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001136 anti-cestodal effect Effects 0.000 description 1
- 230000001679 anti-nematodal effect Effects 0.000 description 1
- 229940033488 antinematodal agent Drugs 0.000 description 1
- YBQWEUNEYYXYOI-UHFFFAOYSA-N arsenamide Chemical compound NC(=O)C1=CC=C([As](SCC(O)=O)SCC(O)=O)C=C1 YBQWEUNEYYXYOI-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960000254 bephenium Drugs 0.000 description 1
- AVWWVJUMXRXPNF-UHFFFAOYSA-N bephenium Chemical compound C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 AVWWVJUMXRXPNF-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- KULDXINYXFTXMO-UHFFFAOYSA-N bis(2-chloroethyl) (3-chloro-4-methyl-2-oxochromen-7-yl) phosphate Chemical compound C1=C(OP(=O)(OCCCl)OCCCl)C=CC2=C1OC(=O)C(Cl)=C2C KULDXINYXFTXMO-UHFFFAOYSA-N 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N bitoscanate Chemical compound S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 229950002418 bitoscanate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950009518 bromoxanide Drugs 0.000 description 1
- 229950005372 brotianide Drugs 0.000 description 1
- 229950004965 bunamidine Drugs 0.000 description 1
- 229950000536 butamisole Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960003475 cambendazole Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BIWJNBZANLAXMG-YQELWRJZSA-N chloordaan Chemical compound ClC1=C(Cl)[C@@]2(Cl)C3CC(Cl)C(Cl)C3[C@]1(Cl)C2(Cl)Cl BIWJNBZANLAXMG-YQELWRJZSA-N 0.000 description 1
- UISUNVFOGSJSKD-UHFFFAOYSA-N chlorfluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=NC=C(C(F)(F)F)C=C1Cl UISUNVFOGSJSKD-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SBPBAQFWLVIOKP-UHFFFAOYSA-N chlorpyrifos Chemical compound CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl SBPBAQFWLVIOKP-UHFFFAOYSA-N 0.000 description 1
- 229960001020 ciclobendazole Drugs 0.000 description 1
- OXLKOMYHDYVIDM-UHFFFAOYSA-N ciclobendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1CC1 OXLKOMYHDYVIDM-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229950010946 clioxanide Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960000275 clorsulon Drugs 0.000 description 1
- 229950004178 closantel Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BXNANOICGRISHX-UHFFFAOYSA-N coumaphos Chemical compound CC1=C(Cl)C(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 BXNANOICGRISHX-UHFFFAOYSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- ZXQYGBMAQZUVMI-UNOMPAQXSA-N cyhalothrin Chemical compound CC1(C)C(\C=C(/Cl)C(F)(F)F)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-UNOMPAQXSA-N 0.000 description 1
- 229960005424 cypermethrin Drugs 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- BSBSDQUZDZXGFN-UHFFFAOYSA-N cythioate Chemical compound COP(=S)(OC)OC1=CC=C(S(N)(=O)=O)C=C1 BSBSDQUZDZXGFN-UHFFFAOYSA-N 0.000 description 1
- 229960002483 decamethrin Drugs 0.000 description 1
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
- DYVLXWPZFQQUIU-WGNDVSEMSA-N derquantel Chemical compound O1C(C)(C)C=COC2=C1C=CC1=C2NC[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 DYVLXWPZFQQUIU-WGNDVSEMSA-N 0.000 description 1
- 229950004278 derquantel Drugs 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 229950010198 diamfenetide Drugs 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- OEBRKCOSUFCWJD-UHFFFAOYSA-N dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 1
- 229950001327 dichlorvos Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- XCBOKUAJQWDYNI-UHFFFAOYSA-N dimethyl (3,5,6-trichloropyridin-2-yl) phosphate Chemical compound COP(=O)(OC)OC1=NC(Cl)=C(Cl)C=C1Cl XCBOKUAJQWDYNI-UHFFFAOYSA-N 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 229940035422 diphenylamine Drugs 0.000 description 1
- IITCWRFYJWUUPC-UHFFFAOYSA-N dipropyl pyridine-2,5-dicarboxylate Chemical compound CCCOC(=O)C1=CC=C(C(=O)OCCC)N=C1 IITCWRFYJWUUPC-UHFFFAOYSA-N 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 229950005765 dithiazanine iodide Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RDYMFSUJUZBWLH-SVWSLYAFSA-N endosulfan Chemical compound C([C@@H]12)OS(=O)OC[C@@H]1[C@]1(Cl)C(Cl)=C(Cl)[C@@]2(Cl)C1(Cl)Cl RDYMFSUJUZBWLH-SVWSLYAFSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229960005362 epsiprantel Drugs 0.000 description 1
- LGUDKOQUWIHXOV-UHFFFAOYSA-N epsiprantel Chemical compound C1C(C2=CC=CC=C2CCC2)N2C(=O)CN1C(=O)C1CCCCC1 LGUDKOQUWIHXOV-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- RIZMRRKBZQXFOY-UHFFFAOYSA-N ethion Chemical compound CCOP(=S)(OCC)SCSP(=S)(OCC)OCC RIZMRRKBZQXFOY-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- JISACBWYRJHSMG-UHFFFAOYSA-N famphur Chemical compound COP(=S)(OC)OC1=CC=C(S(=O)(=O)N(C)C)C=C1 JISACBWYRJHSMG-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960005282 febantel Drugs 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- WDQNIWFZKXZFAY-UHFFFAOYSA-M fentin acetate Chemical compound CC([O-])=O.C1=CC=CC=C1[Sn+](C=1C=CC=CC=1)C1=CC=CC=C1 WDQNIWFZKXZFAY-UHFFFAOYSA-M 0.000 description 1
- BFWMWWXRWVJXSE-UHFFFAOYSA-M fentin hydroxide Chemical compound C=1C=CC=CC=1[Sn](C=1C=CC=CC=1)(O)C1=CC=CC=C1 BFWMWWXRWVJXSE-UHFFFAOYSA-M 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- YOWNVPAUWYHLQX-UHFFFAOYSA-N fluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C(OC=2C(=CC(=CN=2)C(F)(F)F)Cl)=C1 YOWNVPAUWYHLQX-UHFFFAOYSA-N 0.000 description 1
- 229950006719 fluazuron Drugs 0.000 description 1
- 229960004500 flubendazole Drugs 0.000 description 1
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 description 1
- GBIHOLCMZGAKNG-CGAIIQECSA-N flucythrinate Chemical compound O=C([C@@H](C(C)C)C=1C=CC(OC(F)F)=CC=1)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 GBIHOLCMZGAKNG-CGAIIQECSA-N 0.000 description 1
- RYLHNOVXKPXDIP-UHFFFAOYSA-N flufenoxuron Chemical compound C=1C=C(NC(=O)NC(=O)C=2C(=CC=CC=2F)F)C(F)=CC=1OC1=CC=C(C(F)(F)F)C=C1Cl RYLHNOVXKPXDIP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 description 1
- 229960004498 fluralaner Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- SZGAAHDUAFVZSS-SFYZADRCSA-N forosamine Chemical compound C[C@@H](O)[C@@H](N(C)C)CCC=O SZGAAHDUAFVZSS-SFYZADRCSA-N 0.000 description 1
- 229950005302 fospirate Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229950002831 haloxon Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- RGNPBRKPHBKNKX-UHFFFAOYSA-N hexaflumuron Chemical compound C1=C(Cl)C(OC(F)(F)C(F)F)=C(Cl)C=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F RGNPBRKPHBKNKX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229950000216 hycanthone Drugs 0.000 description 1
- MFZWMTSUNYWVBU-UHFFFAOYSA-N hycanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(CO)=CC=C2NCCN(CC)CC MFZWMTSUNYWVBU-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical class [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 229940056881 imidacloprid Drugs 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical group [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002547 isoxazolines Chemical class 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- GEPDYQSQVLXLEU-AATRIKPKSA-N methyl (e)-3-dimethoxyphosphoryloxybut-2-enoate Chemical compound COC(=O)\C=C(/C)OP(=O)(OC)OC GEPDYQSQVLXLEU-AATRIKPKSA-N 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WLLGXSLBOPFWQV-OTHKPKEBSA-N molport-035-783-878 Chemical compound C([C@H]1C=C2)[C@H]2C2C1C(=O)N(CC(CC)CCCC)C2=O WLLGXSLBOPFWQV-OTHKPKEBSA-N 0.000 description 1
- 229950003439 monepantel Drugs 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- 229960005121 morantel Drugs 0.000 description 1
- FGGFIMIICGZCCJ-UHFFFAOYSA-N n,n-dibutyl-4-hexoxynaphthalene-1-carboximidamide Chemical compound C1=CC=C2C(OCCCCCC)=CC=C(C(=N)N(CCCC)CCCC)C2=C1 FGGFIMIICGZCCJ-UHFFFAOYSA-N 0.000 description 1
- JNEZCZPNQCQCFK-UHFFFAOYSA-N n-[4-[2-[2-(4-acetamidophenoxy)ethoxy]ethoxy]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OCCOCCOC1=CC=C(NC(C)=O)C=C1 JNEZCZPNQCQCFK-UHFFFAOYSA-N 0.000 description 1
- WRPRKPMHLLGGIZ-UHFFFAOYSA-N n-[4-bromo-2-(trifluoromethyl)phenyl]-3-tert-butyl-2-hydroxy-6-methyl-5-nitrobenzamide Chemical compound CC1=C([N+]([O-])=O)C=C(C(C)(C)C)C(O)=C1C(=O)NC1=CC=C(Br)C=C1C(F)(F)F WRPRKPMHLLGGIZ-UHFFFAOYSA-N 0.000 description 1
- QNSIFYWAPWSAIJ-UHFFFAOYSA-N naftalofos Chemical compound C1=CC(C(N(OP(=O)(OCC)OCC)C2=O)=O)=C3C2=CC=CC3=C1 QNSIFYWAPWSAIJ-UHFFFAOYSA-N 0.000 description 1
- 229950011528 naftalofos Drugs 0.000 description 1
- BUYMVQAILCEWRR-UHFFFAOYSA-N naled Chemical compound COP(=O)(OC)OC(Br)C(Cl)(Cl)Br BUYMVQAILCEWRR-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- XULACPAEUUWKFX-UHFFFAOYSA-N niclofolan Chemical compound C1=C(Cl)C=C([N+]([O-])=O)C(O)=C1C1=CC(Cl)=CC([N+]([O-])=O)=C1O XULACPAEUUWKFX-UHFFFAOYSA-N 0.000 description 1
- 229950006977 niclofolan Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960005130 niridazole Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SVMGVZLUIWGYPH-UHFFFAOYSA-N nitroscanate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(N=C=S)C=C1 SVMGVZLUIWGYPH-UHFFFAOYSA-N 0.000 description 1
- 229950009909 nitroscanate Drugs 0.000 description 1
- 229930187416 nodulisporic acid Natural products 0.000 description 1
- UNCVXXVJJXJZII-UHFFFAOYSA-N nodulisporic acid A Natural products C1CC2C(C)(C=CC=C(C)C(O)=O)C(O)CCC2(C)C2(C)C1CC1=C2N2C(C(=C)C)C(=O)C3=C(C(O)C4C(OC(C)(C)C=C44)(C)C)C4=CC1=C32 UNCVXXVJJXJZII-UHFFFAOYSA-N 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- 229950008687 oltipraz Drugs 0.000 description 1
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960000462 oxamniquine Drugs 0.000 description 1
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 1
- 229960000535 oxantel Drugs 0.000 description 1
- VRYKTHBAWRESFI-VOTSOKGWSA-N oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 description 1
- 229960004454 oxfendazole Drugs 0.000 description 1
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 1
- 229960002762 oxibendazole Drugs 0.000 description 1
- JYWIYHUXVMAGLG-UHFFFAOYSA-N oxyclozanide Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl JYWIYHUXVMAGLG-UHFFFAOYSA-N 0.000 description 1
- 229950003126 oxyclozanide Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229930188716 paraherquamide Natural products 0.000 description 1
- UVZZDDLIOJPDKX-UHFFFAOYSA-N paraherquamide A Natural products O1C(C)(C)C=COC2=C1C=CC1=C2NC(=O)C11C(C)(C)C2CC3(N(C4)CCC3(C)O)C(=O)N(C)C42C1 UVZZDDLIOJPDKX-UHFFFAOYSA-N 0.000 description 1
- 208000029380 parasitic ectoparasitic infectious disease Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 229950007337 parbendazole Drugs 0.000 description 1
- 229960000490 permethrin Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960003536 phenothrin Drugs 0.000 description 1
- IOUNQDKNJZEDEP-UHFFFAOYSA-N phosalone Chemical compound C1=C(Cl)C=C2OC(=O)N(CSP(=S)(OCC)OCC)C2=C1 IOUNQDKNJZEDEP-UHFFFAOYSA-N 0.000 description 1
- LMNZTLDVJIUSHT-UHFFFAOYSA-N phosmet Chemical compound C1=CC=C2C(=O)N(CSP(=S)(OC)OC)C(=O)C2=C1 LMNZTLDVJIUSHT-UHFFFAOYSA-N 0.000 description 1
- YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- ATROHALUCMTWTB-OWBHPGMISA-N phoxim Chemical compound CCOP(=S)(OCC)O\N=C(\C#N)C1=CC=CC=C1 ATROHALUCMTWTB-OWBHPGMISA-N 0.000 description 1
- 229950001664 phoxim Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
- BZNDWPRGXNILMS-VQHVLOKHSA-N propetamphos Chemical compound CCNP(=S)(OC)O\C(C)=C\C(=O)OC(C)C BZNDWPRGXNILMS-VQHVLOKHSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960005134 pyrantel Drugs 0.000 description 1
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- 229940070846 pyrethrins Drugs 0.000 description 1
- 239000002728 pyrethroid Substances 0.000 description 1
- 229950007312 pyrvinium chloride Drugs 0.000 description 1
- 229960001077 pyrvinium pamoate Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- NEMNPWINWMHUMR-UHFFFAOYSA-N rafoxanide Chemical compound OC1=C(I)C=C(I)C=C1C(=O)NC(C=C1Cl)=CC=C1OC1=CC=C(Cl)C=C1 NEMNPWINWMHUMR-UHFFFAOYSA-N 0.000 description 1
- 229950002980 rafoxanide Drugs 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940108410 resmethrin Drugs 0.000 description 1
- VEMKTZHHVJILDY-FIWHBWSRSA-N resmethrin Chemical compound CC1(C)[C@H](C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-FIWHBWSRSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical class OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 description 1
- 229960005393 sarolaner Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ITCAUAYQCALGGV-XTICBAGASA-M sodium;(1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound [Na+].C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C([O-])=O ITCAUAYQCALGGV-XTICBAGASA-M 0.000 description 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- CTPKSRZFJSJGML-UHFFFAOYSA-N sulfiram Chemical compound CCN(CC)C(=S)SC(=S)N(CC)CC CTPKSRZFJSJGML-UHFFFAOYSA-N 0.000 description 1
- 229950008316 sulfiram Drugs 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960000621 suramin sodium Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- QYPNKSZPJQQLRK-UHFFFAOYSA-N tebufenozide Chemical compound C1=CC(CC)=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYPNKSZPJQQLRK-UHFFFAOYSA-N 0.000 description 1
- CJDWRQLODFKPEL-UHFFFAOYSA-N teflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC(Cl)=C(F)C(Cl)=C1F CJDWRQLODFKPEL-UHFFFAOYSA-N 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- OEJNXTAZZBRGDN-UHFFFAOYSA-N toxaphene Chemical compound ClC1C(Cl)C2(Cl)C(CCl)(CCl)C(=C)C1(Cl)C2(Cl)Cl OEJNXTAZZBRGDN-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KVSKGMLNBAPGKH-UHFFFAOYSA-N tribromosalicylanilide Chemical compound OC1=C(Br)C=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 KVSKGMLNBAPGKH-UHFFFAOYSA-N 0.000 description 1
- 229950001807 tribromsalan Drugs 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- XAIPTRIXGHTTNT-UHFFFAOYSA-N triflumuron Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)NC(=O)C1=CC=CC=C1Cl XAIPTRIXGHTTNT-UHFFFAOYSA-N 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N49/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds containing the group, wherein m+n>=1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group, wherein A means a carbon atom or Y, n>=0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Insects & Arthropods (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to topical veterinary formulations for controlling ectoparasites, in particular fleas and ticks, on animals. More particularly, the invention relates to topical formulations comprising a 1-N-phenylpyrazole (fipronil) and a second active which is an insect growth regulator (IGR) and a veterinarily acceptable liquid carrier. The invention further relates to methods and uses of said formulations in eradicating, controlling and preventing parasite infestation in animals.
Description
VETERINARY FORMULATIONS
The present invention relates to topical veterinary formulations for controlling ectoparasites, in particular fleas and ticks, on animals. More particularly, the invention relates to topical formulations comprising a 1-N-phenylpyrazole (fipronil) and a second active which is an insect growth regulator (IGR) and a veterinarily acceptable liquid carrier. The invention further relates to methods and uses of said formulations in eradicating, controlling and preventing parasite infestation in animals.
BACKGROUND TO THE INVENTION
Animals such as mammals and birds are often susceptible to parasite infestations/infections. These parasites may be ectoparasites, such as insects, and endoparasites such as filariae and other worms. Domesticated animals, such as cats and dogs, are often infested with one or more of the following ectoparasites:
fleas (Ctenocephalides spp., such as Ctenocephalides fells and the like), ticks (Rhipicephalus spp., lxodes spp., Dermacentor spp., Amblyoma spp., and the like), mites (Demodex spp., Sarcoptes spp., Otodectes spp., and the like), lice (Trichodectes spp., Cheyletiella spp., Lignonathus spp. and the like), mosquitoes (Aedes spp., Culux spp., Anopheles spp. and the like) and flies (Hematobia spp., Musca spp., Stomoxys spp., Dematobia spp., Coclyomia spp. and the like).
Fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress.
Moreover, fleas are also vectors of pathogenic agents in animals, such as dog tapeworm (Dipylidium caninum), and humans.
Similarly, ticks are also harmful to the physical and psychological health of the animal or human. However, the most serious problem associated with ticks is that they are the vector of pathogenic agents in both humans and animals. Major diseases which are caused by ticks include borrelioses (Lyme disease caused by Borrelia burgdorfen), babesioses (or piroplasmoses caused by Babesia spp.) and rickettsioses (also known as Rocky Mountain spotted fever). Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host.
Moreover, mites and lice are particularly difficult to combat since there are very few active substances which act on these parasites and they require frequent treatment.
Likewise, farm animals are also susceptible to parasite infestations. For example, cattle are affected by a large number of parasites. A parasite which is very prevalent among farm animals is the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus. Ticks, such as Boophilus microplus, are particularly difficult to control because they live in the pasture where farm animals graze. Other important parasites of cattle and sheep are listed as follows: myiases-causing flies such as Dermatobia hominis (known as Berne in Brazil) and Cochlyomia hominivorax (greenbottle); sheep myiases-causing flies such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). These are flies whose larva constitutes the animal parasite; flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly); lice such as Linognathus vitulorum, etc.;
and mites such as Sarcoptes scabiei and Psoroptes ovis.
1-Arylpyrazoles are a class of chemicals well known in the art, and certain compounds in this class have been found to be potently active against a wide range of pests and parasites that are harmful to animals and plants. For example, 1-arylpyrazole derivatives are known in the art to prevent, treat or control ectoparasitic infestations in mammals, such as cats, dogs and cattle. Certain 1-arylpyrazoles and their use against pests are described in US Patent Publication Nos. US 2005/0182048; US 2006/0135778; US
2008/0132487; US 2008/0031902; US Patent Nos. 4,963,575; 5,122,530; 5,232,940;
5,236,938; 5,246,255; 5,547,974; 5,567,429; 5,576,429; 5,608,077; 5,714,191;
5,814,652;
5,885,607; 5,567,429; 5,817,688; 5,885,607; 5,916,618; 5,922,885; 5,994,386;
6,001,384;
6,010,710; 6,057,355; 6,069,157; 6,083,519; 6,090,751; 6,096,329; 6,124,339;
6,180,798;
6,335,357; 6,350,771; 6,372,774; 6,395,906; 6,413,542; 6,685,954; and 7,468,381. See also: EP 0 234 119, EP 0 295 117, EP 0 352 944, EP 0 500 209, EP 0 780 378, EP
686, and EP 0 948 485, all of which are incorporated herein by reference in their entirety.
The present invention relates to topical veterinary formulations for controlling ectoparasites, in particular fleas and ticks, on animals. More particularly, the invention relates to topical formulations comprising a 1-N-phenylpyrazole (fipronil) and a second active which is an insect growth regulator (IGR) and a veterinarily acceptable liquid carrier. The invention further relates to methods and uses of said formulations in eradicating, controlling and preventing parasite infestation in animals.
BACKGROUND TO THE INVENTION
Animals such as mammals and birds are often susceptible to parasite infestations/infections. These parasites may be ectoparasites, such as insects, and endoparasites such as filariae and other worms. Domesticated animals, such as cats and dogs, are often infested with one or more of the following ectoparasites:
fleas (Ctenocephalides spp., such as Ctenocephalides fells and the like), ticks (Rhipicephalus spp., lxodes spp., Dermacentor spp., Amblyoma spp., and the like), mites (Demodex spp., Sarcoptes spp., Otodectes spp., and the like), lice (Trichodectes spp., Cheyletiella spp., Lignonathus spp. and the like), mosquitoes (Aedes spp., Culux spp., Anopheles spp. and the like) and flies (Hematobia spp., Musca spp., Stomoxys spp., Dematobia spp., Coclyomia spp. and the like).
Fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress.
Moreover, fleas are also vectors of pathogenic agents in animals, such as dog tapeworm (Dipylidium caninum), and humans.
Similarly, ticks are also harmful to the physical and psychological health of the animal or human. However, the most serious problem associated with ticks is that they are the vector of pathogenic agents in both humans and animals. Major diseases which are caused by ticks include borrelioses (Lyme disease caused by Borrelia burgdorfen), babesioses (or piroplasmoses caused by Babesia spp.) and rickettsioses (also known as Rocky Mountain spotted fever). Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host.
Moreover, mites and lice are particularly difficult to combat since there are very few active substances which act on these parasites and they require frequent treatment.
Likewise, farm animals are also susceptible to parasite infestations. For example, cattle are affected by a large number of parasites. A parasite which is very prevalent among farm animals is the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus. Ticks, such as Boophilus microplus, are particularly difficult to control because they live in the pasture where farm animals graze. Other important parasites of cattle and sheep are listed as follows: myiases-causing flies such as Dermatobia hominis (known as Berne in Brazil) and Cochlyomia hominivorax (greenbottle); sheep myiases-causing flies such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). These are flies whose larva constitutes the animal parasite; flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly); lice such as Linognathus vitulorum, etc.;
and mites such as Sarcoptes scabiei and Psoroptes ovis.
1-Arylpyrazoles are a class of chemicals well known in the art, and certain compounds in this class have been found to be potently active against a wide range of pests and parasites that are harmful to animals and plants. For example, 1-arylpyrazole derivatives are known in the art to prevent, treat or control ectoparasitic infestations in mammals, such as cats, dogs and cattle. Certain 1-arylpyrazoles and their use against pests are described in US Patent Publication Nos. US 2005/0182048; US 2006/0135778; US
2008/0132487; US 2008/0031902; US Patent Nos. 4,963,575; 5,122,530; 5,232,940;
5,236,938; 5,246,255; 5,547,974; 5,567,429; 5,576,429; 5,608,077; 5,714,191;
5,814,652;
5,885,607; 5,567,429; 5,817,688; 5,885,607; 5,916,618; 5,922,885; 5,994,386;
6,001,384;
6,010,710; 6,057,355; 6,069,157; 6,083,519; 6,090,751; 6,096,329; 6,124,339;
6,180,798;
6,335,357; 6,350,771; 6,372,774; 6,395,906; 6,413,542; 6,685,954; and 7,468,381. See also: EP 0 234 119, EP 0 295 117, EP 0 352 944, EP 0 500 209, EP 0 780 378, EP
686, and EP 0 948 485, all of which are incorporated herein by reference in their entirety.
2 A novel class of 1-N-arylpyrazole-based insecticides has been described in patents EP295217 and EP352944. The compounds of the classes defined in these patents are highly active, and one of these compounds (1-(2,6-C12-4-CF3phenyI)-3-CN-4-(SO-CF3)-5-NH2pyrazole), whose common name is fipronil, has proven to be highly effective against mammal ectoparasites and in particular, but not exclusively, fleas, ticks, flies and myiases.
Fipronil is the active ingredient in the commercial veterinary products FRONTLINE and FRONTLINE Plus.
The class of acaricides or insecticides known as insect growth regulators (IGRs) is well known to the practitioner and represents a wide range of different chemical classes.
These compounds all act by interfering with the development or growth of the insect pests. Insect growth regulator compounds typically act either by blocking the development of the immature stages (eggs and larvae) into adult stages, or by inhibiting the synthesis of chitin. Insect growth regulators are described, for example, in U.S. Patent Nos.
Fipronil is the active ingredient in the commercial veterinary products FRONTLINE and FRONTLINE Plus.
The class of acaricides or insecticides known as insect growth regulators (IGRs) is well known to the practitioner and represents a wide range of different chemical classes.
These compounds all act by interfering with the development or growth of the insect pests. Insect growth regulator compounds typically act either by blocking the development of the immature stages (eggs and larvae) into adult stages, or by inhibiting the synthesis of chitin. Insect growth regulators are described, for example, in U.S. Patent Nos.
3,748,356, 3,818,047, 4,225,598, 4,798,837, 4,751,225, EP 0 179 022 or U.K. 2 as well as U.S. Patent Nos. 6,096,329, 6,685,954 and US 5,439,924 (all incorporated herein by reference).
Combinations comprising a 1-N-arylpyrazole and an IGR are already well known in the art. For example, US 6,096,329 (incorporated by reference) describes a spot-on composition for the long lasting protection against fleas and ticks on mammals which comprises fipronil, a compound which mimics juvenile hormones and at least one customary spot-on formulation adjuvant. In addition to the two actives, the spot-on compositions described in US 6,096,329 advantageously comprise a crystallization inhibitor, an organic solvent having a dielectric constant of between 10 and 35, and an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40. The co-solvent is volatile and serves as a drying promoter, whilst the crystallisation inhibitor prevents precipitation of the actives out of solution, which can often be problematic in low volume-high concentration solutions.
Spot-on formulations are capable of topically delivering an antiparasitic agent to a limited area of the host. For example, U.S. Patent Nos. 5,045,536, 426,333; 6,482,425;
6,962,713; and 6,998,131, all incorporated herein by reference, describe spot-on formulations. WO 01/95715, also incorporated herein by reference, describes a method for controlling ectoparasites in small rodents as well as interrupting or preventing the diseases caused by arthropods or small rodents, which comprise applying topical formulations, such as spot-on compositions, to the skin, or hair of the rodents.
Spot-on formulations are typically applied to a localized region of the animal's skin, usually in one or two spots between the animal's shoulder blades. Once applied, the actives distribute over the animal's whole body from the point of application. Cochet and co-workers reported the distribution of fipronil to the stratum corneum, the viable epidermis and the sebaceous glands and epithelial layers of beagle dogs after spot-on administration (see Cochet etal., Eur. J. Drug Metab. Pharmacokinet., 1997, 22(3), 211-216). Using 140 radiolabeled drug, the publication demonstrated that fipronil is displaced from the point of application and distributed to the whole skin, where it was persistently detected for up to 56 days after treatment. The benefits of spot-on application, in terms of both efficacy and ease of application, are reflected in the commercial success of FRONTLINE Plus, a spot-on formulation comprising fipronil and methoprene, which has been a worldwide leading veterinary product for many years.
The present invention seeks to provide alternative and/or improved topical formulations comprising fipronil in combination with an IGR.
STATEMENT OF INVENTION
A first aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
Combinations comprising a 1-N-arylpyrazole and an IGR are already well known in the art. For example, US 6,096,329 (incorporated by reference) describes a spot-on composition for the long lasting protection against fleas and ticks on mammals which comprises fipronil, a compound which mimics juvenile hormones and at least one customary spot-on formulation adjuvant. In addition to the two actives, the spot-on compositions described in US 6,096,329 advantageously comprise a crystallization inhibitor, an organic solvent having a dielectric constant of between 10 and 35, and an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40. The co-solvent is volatile and serves as a drying promoter, whilst the crystallisation inhibitor prevents precipitation of the actives out of solution, which can often be problematic in low volume-high concentration solutions.
Spot-on formulations are capable of topically delivering an antiparasitic agent to a limited area of the host. For example, U.S. Patent Nos. 5,045,536, 426,333; 6,482,425;
6,962,713; and 6,998,131, all incorporated herein by reference, describe spot-on formulations. WO 01/95715, also incorporated herein by reference, describes a method for controlling ectoparasites in small rodents as well as interrupting or preventing the diseases caused by arthropods or small rodents, which comprise applying topical formulations, such as spot-on compositions, to the skin, or hair of the rodents.
Spot-on formulations are typically applied to a localized region of the animal's skin, usually in one or two spots between the animal's shoulder blades. Once applied, the actives distribute over the animal's whole body from the point of application. Cochet and co-workers reported the distribution of fipronil to the stratum corneum, the viable epidermis and the sebaceous glands and epithelial layers of beagle dogs after spot-on administration (see Cochet etal., Eur. J. Drug Metab. Pharmacokinet., 1997, 22(3), 211-216). Using 140 radiolabeled drug, the publication demonstrated that fipronil is displaced from the point of application and distributed to the whole skin, where it was persistently detected for up to 56 days after treatment. The benefits of spot-on application, in terms of both efficacy and ease of application, are reflected in the commercial success of FRONTLINE Plus, a spot-on formulation comprising fipronil and methoprene, which has been a worldwide leading veterinary product for many years.
The present invention seeks to provide alternative and/or improved topical formulations comprising fipronil in combination with an IGR.
STATEMENT OF INVENTION
A first aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
4 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A second aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
A third aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
A fourth aspect of the invention relates to a topical formulation comprising:
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A fifth aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene
A second aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
A third aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
A fourth aspect of the invention relates to a topical formulation comprising:
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A fifth aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene
5 glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A sixth aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A seventh aspect of the invention relates to a topical formulation as described above for use in treating or controlling ectoparasites on an animal.
An eighth aspect of the invention relates to a method of treating or controlling ectoparasites on an animal, said method comprising topically applying a topical composition as described above.
Formulations according to the invention have been shown to exhibit excellent efficacy against fleas, both in terms of duration of efficacy and their effect on inhibition of egg hatching. Moreover, certain embodiments of the invention offer one or more additional advantages, including but not limited to, simplicity (fewer components), ease of formulation and/or improved efficacy. The spot-on formulations according to the invention are particularly advantageous owing to their efficacy, the speed of action and the pleasant appearance of the animal's fur after application and drying.
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A sixth aspect of the invention relates to a topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
A seventh aspect of the invention relates to a topical formulation as described above for use in treating or controlling ectoparasites on an animal.
An eighth aspect of the invention relates to a method of treating or controlling ectoparasites on an animal, said method comprising topically applying a topical composition as described above.
Formulations according to the invention have been shown to exhibit excellent efficacy against fleas, both in terms of duration of efficacy and their effect on inhibition of egg hatching. Moreover, certain embodiments of the invention offer one or more additional advantages, including but not limited to, simplicity (fewer components), ease of formulation and/or improved efficacy. The spot-on formulations according to the invention are particularly advantageous owing to their efficacy, the speed of action and the pleasant appearance of the animal's fur after application and drying.
6
7 PCT/US2016/062364 DETAILED DESCRIPTION
Aspects of the invention and further preferred embodiments are presented in the accompanying claims and numbered paragraphs.
In this disclosure and in the claims, terms such as "comprises," "comprising,"
"containing"
and "having" and the like can mean "includes," "including," and the like. The term "consisting essentially of" or "consists essentially" is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
Certain embodiments of the invention relate to topical formulations that do not contain an organic co-solvent, wherein said organic co-solvent has a boiling point of below 100 C
and a dielectric constant of between 10 and 40. Typically, prior art spot-on formulations comprise an organic co-solvent to aid dissolution of the actives, and also act as a drying promoter.
Examples of co-solvents falling within this definition include absolute ethanol, methanol and isopropanol.
Thus, in certain preferred embodiments, the invention relates to formulations that do not contain ethanol, methanol or isopropanol.
Surprisingly, studies by the applicant have demonstrated that the presence of a co-solvent is not critical in spot-on formulations. In fact, studies by the applicant have demonstrated that certain formulations which lack a co-solvent actually exhibit comparable duration of efficacy with that of the commercial product Frontline Plus. For example, this is observed for formulations where the solvent is a glycol ether (e.g. DGME), or an optionally substituted pyrrolidone (e.g. NMP). Further details of these studies are set forth in the accompanying examples.
Other embodiments of the invention relate to topical compositions that do not contain a crystallisation inhibitor.
As used herein, the term "crystallisation inhibitor" refers to a compound that is capable of inhibiting precipitation of the actives (e.g. fipronil and/or the IGR, where the IGR is a solid at room temperature) from the veterinarily acceptable carrier.
The skilled person would be familiar with the use of crystallisation inhibitors in topical compositions, particularly in the context of high concentration-low volume compositions such as spot-on compositions. Crystallisation inhibitors are typically used in an amount of from about 1 to about 20% (w/v), preferably from about 5 to about 15% w/v.
In certain preferred embodiments of the invention, the formulation is completely free from crystallisation inhibitor.
Typically, the skilled person would be able to identify suitable crystallization inhibitors by way of a simple laboratory test. By way of illustration, one non-limiting example of such a simple laboratory test is set out as follows: 0.3 ml of a solution of fipronil is added to the veterinarily acceptable carrier along with 10% of the purported crystallisation inhibitor, and the mixture is deposited on a glass slide at 20 C and left for 24 hours, after which it is observed with the naked eye whether there are crystals present. If the compound satisfies the test, there will be fewer than 10 crystals, preferably less than 5 crystals, even more preferably, zero crystals on the glass slide. Typically, the skilled person would carry out the test under standard laboratory conditions (e.g. in a weighing cabinet or similar such apparatus to avoid excessive air flow or variable conditions during the test).
Suitable crystallisation inhibitors in the context of the present invention include, but are not limited to the following:
- polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, acrylic derivatives such as
Aspects of the invention and further preferred embodiments are presented in the accompanying claims and numbered paragraphs.
In this disclosure and in the claims, terms such as "comprises," "comprising,"
"containing"
and "having" and the like can mean "includes," "including," and the like. The term "consisting essentially of" or "consists essentially" is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
Certain embodiments of the invention relate to topical formulations that do not contain an organic co-solvent, wherein said organic co-solvent has a boiling point of below 100 C
and a dielectric constant of between 10 and 40. Typically, prior art spot-on formulations comprise an organic co-solvent to aid dissolution of the actives, and also act as a drying promoter.
Examples of co-solvents falling within this definition include absolute ethanol, methanol and isopropanol.
Thus, in certain preferred embodiments, the invention relates to formulations that do not contain ethanol, methanol or isopropanol.
Surprisingly, studies by the applicant have demonstrated that the presence of a co-solvent is not critical in spot-on formulations. In fact, studies by the applicant have demonstrated that certain formulations which lack a co-solvent actually exhibit comparable duration of efficacy with that of the commercial product Frontline Plus. For example, this is observed for formulations where the solvent is a glycol ether (e.g. DGME), or an optionally substituted pyrrolidone (e.g. NMP). Further details of these studies are set forth in the accompanying examples.
Other embodiments of the invention relate to topical compositions that do not contain a crystallisation inhibitor.
As used herein, the term "crystallisation inhibitor" refers to a compound that is capable of inhibiting precipitation of the actives (e.g. fipronil and/or the IGR, where the IGR is a solid at room temperature) from the veterinarily acceptable carrier.
The skilled person would be familiar with the use of crystallisation inhibitors in topical compositions, particularly in the context of high concentration-low volume compositions such as spot-on compositions. Crystallisation inhibitors are typically used in an amount of from about 1 to about 20% (w/v), preferably from about 5 to about 15% w/v.
In certain preferred embodiments of the invention, the formulation is completely free from crystallisation inhibitor.
Typically, the skilled person would be able to identify suitable crystallization inhibitors by way of a simple laboratory test. By way of illustration, one non-limiting example of such a simple laboratory test is set out as follows: 0.3 ml of a solution of fipronil is added to the veterinarily acceptable carrier along with 10% of the purported crystallisation inhibitor, and the mixture is deposited on a glass slide at 20 C and left for 24 hours, after which it is observed with the naked eye whether there are crystals present. If the compound satisfies the test, there will be fewer than 10 crystals, preferably less than 5 crystals, even more preferably, zero crystals on the glass slide. Typically, the skilled person would carry out the test under standard laboratory conditions (e.g. in a weighing cabinet or similar such apparatus to avoid excessive air flow or variable conditions during the test).
Suitable crystallisation inhibitors in the context of the present invention include, but are not limited to the following:
- polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, acrylic derivatives such as
8 methacrylates and the like, - anionic surfactants such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate; triethanolamine stearate; sodium abietate; alkyl sulphates, in particular sodium lauryl sulphate and sodium cetyl sulphate;
sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids, in particular those derived from coconut oil, - cationic surfactants such as water-soluble quaternary ammonium salts of formula N+R'R"R"R",Y- in which the radicals R are optionally hydroxylated hydrocarbon radicals and Y- is an anion of a strong acid such as the halide, sulphate and sulphonate anions;
cetyltrimetylammonium bromide is among the cationic surfactants 9 an be used, - amine salts of formula N+R'R'XR" in which the radicals R are optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is among the cationic surfactants which can be used, - nonionic surfactants such as optionally polyoxyethylenated sorbitan esters, in particular polysorbate 80, polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide, - amphoteric surfactants such as substituted lauryl compounds of betaine, or preferably a mixture of at least two of these crystallization inhibitors.
In certain preferred embodiments of the invention, the formulation is completely free from the above-recited compounds listed as crystallisation inhibitors.
In certain preferred embodiments, the formulation contains less than about 1 %
w/v of one or more of the above-mentioned compounds listed as crystallisation inhibitors, more preferably, less than about 0.5 % w/v, even more preferably, less than about 0.1 % w/v, more preferably still, less than about 0.05 % or 0.01 % w/v of the formulation.
Advantageously, clinical studies by the applicant have demonstrated that spot-on formulations according to the invention which lack a crystallisation inhibitor exhibit
sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids, in particular those derived from coconut oil, - cationic surfactants such as water-soluble quaternary ammonium salts of formula N+R'R"R"R",Y- in which the radicals R are optionally hydroxylated hydrocarbon radicals and Y- is an anion of a strong acid such as the halide, sulphate and sulphonate anions;
cetyltrimetylammonium bromide is among the cationic surfactants 9 an be used, - amine salts of formula N+R'R'XR" in which the radicals R are optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is among the cationic surfactants which can be used, - nonionic surfactants such as optionally polyoxyethylenated sorbitan esters, in particular polysorbate 80, polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide, - amphoteric surfactants such as substituted lauryl compounds of betaine, or preferably a mixture of at least two of these crystallization inhibitors.
In certain preferred embodiments of the invention, the formulation is completely free from the above-recited compounds listed as crystallisation inhibitors.
In certain preferred embodiments, the formulation contains less than about 1 %
w/v of one or more of the above-mentioned compounds listed as crystallisation inhibitors, more preferably, less than about 0.5 % w/v, even more preferably, less than about 0.1 % w/v, more preferably still, less than about 0.05 % or 0.01 % w/v of the formulation.
Advantageously, clinical studies by the applicant have demonstrated that spot-on formulations according to the invention which lack a crystallisation inhibitor exhibit
9 surprisingly good duration of efficacy against fleas. This is observed where the solvent is a glycol ether (e.g. DGME), or an optionally substituted pyrrolidone (e.g.
NMP). Further details of these studies are set forth in the accompanying examples.
In certain particularly preferred embodiments of the invention, the formulations lack both an organic co-solvent, wherein said organic co-solvent has a boiling point of below 100 C
and a dielectric constant of between 10 and 40, and a crystallisation inhibitor as desribed above.
Thus, in certain particularly preferred embodiments of the invention, the formulations do not contain a crystallisation inhibitor as described above, nor do they contain ethanol, methanol or isopropanol.
In one embodiment, the formulations comprise a crystallisation inhibitor as described above, but do not comprise a co-solvent as described above.
In one embodiment, the formulations comprise a co-solvent as described above, but do not comprise a crystallisation inhibitor as described above.
In certain highly preferred embodiments, the formulations consist essentially of, or consist of, fipronil, an IGR, and a veterinarily acceptable carrier which is an optionally substituted pyrrolidone or a glycol ether, and optionally one or more antioxidants.
In other embodiments, the formulations may contain fipronil, an IGR and one or more additional active agents in a veterinarily acceptable carrier.
Insect Growth Regulators The compositions of the invention contain one or more insect growth regulators (IGRs). In one embodiment, the IGR is a compound which mimics juvenile hormones. Suitable examples include:
azadirachtin (Agridyne);
diofenolan (Ciba Geigy);
fenoxycarb (Ciba Geigy);
hydroprene (Sandoz);
kinoprene (Sandoz);
methoprene (Sandoz);
pyriproxyfen (Sumitomo/Mgk);
tetrahydroazadirachtin (Agridyne); and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridazin-3(2H)-one.
In another embodiment, the IGR is a chitin-synthesis inhibitor. Suitable examples include:
chlorfluazuron (Ishihara Sangyo);
cyromazine (Ciba Geigy);
diflubenzuron (Solvay Duphar);
fluazuron (Ciba Geigy);
flucycloxuron (Solvay Duphar);
flufenoxuron (Cyanamid);
hexaflumuron (Dow Elanco);
lufenuron (Ciba Geigy);
tebufenozide (Rohm & Haas);
teflubenzuron (Cyanamid); and triflumuron (Bayer).
The above compounds are defined by their international common name (The Pesticide Manual, 10th edition, 1994, Ed. Clive Tomlin, Great Britain).
As chitin-synthesis inhibitors, mention may also be made of compounds such as 142,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, 1-(2,6-difluorobenzoyI)-3- (2-fluoro-4-(1,1,2,2-tetrafluoroethoxy)phenylurea and 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-trifluoromethyl)phenylurea. Novaluron (Isagro, Italian company) may also be mentioned as an IGR.
In certain preferred embodiments, the IGR is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoy1)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one In certain highly preferred embodiments, the IGR is methoprene, more preferable S-methoprene.
In certain other embodiments, the IGR is pyriproxyfen.
In certain preferred embodiments, the IGR is present in an amount of from about 1 to about 20 % (w/v).
In certain more preferred embodiments, the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
Fipronil The formulations of the present invention all contain fipronil, the compound known as (1-(2,6-C12-4-CF3phenyI)-3-CN-4-(SO-CF3)-5-NH2pyrazole).
Fipronil and related compounds may be prepared according to one or other of the processes described in patent applications WO-A-87/3781, 93/6089, 94/21606 or European patent application EP-A-0,295,117, or any other process which falls within the competence of a specialist skilled in the art of chemical synthesis.
In certain preferred embodiments of the invention, the fipronil is present in an amount of from about 1 to about 20 % (w/v).
Preferably, the fipronil is present in an amount of from about 5 to about 15 %
(w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
The proportions, by weight, of compounds of fipronil and the IGR are preferably between 80/20 and 20/80.
Additional Active Agents In another embodiment of the invention, one or more macrocyclic lactones, which act as an acaricide, an anthelmintic agent and/or an insecticide, can be included in the compositions of the invention. For the avoidance of doubt, the term "macrocyclic lactone"
as used herein includes both naturally occurring and synthetic or semi-synthetic avermectin and milbemycin compounds.
The macrocyclic lactones that may be used in the compositions of the invention include, but are not limited to, the naturally produced avermectins (e.g. including the components designated as Aia, Aib, A2a, A2b, Bia, Bib, B2a and B2b) and milbemycin compounds, semisynthetic avermectins and milbemycins, avermectin monosaccharide compounds and avermectin aglycone compounds. Examples of macrocyclic lactone compounds that may be used in the compositions include, but are not limited to, abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, ML-1,694,554 and milbemycins including, but not limited to, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin and nemadectin.
Also included are the 5-oxo and 5-oxime derivatives of said avermectins and milbemycins.
The macrocyclic lactone compounds are known in the art and can easily be obtained commercially or through synthesis techniques known in the art. Reference is made to the widely available technical and commercial literature. For avermectins, ivermectin and abamectin, reference may be made, for example, to the work "Ivermectin and Abamectin", 1989, by M.H. Fischer and H. Mrozik, VVilliam C. Campbell, published by Springer Verlag., or Albers-Schonberg et al. (1981), "Avermectins Structure Determination", J.
Am. Chem.
Soc., 103, 4216-4221. For doramectin, "Veterinary Parasitology", vol. 49, No.
1, July 1993, 5-15 may be consulted. For milbemycins, reference may be made, inter alia, to Davies H.G. et al., 1986, "Avermectins and Milbemycins", Nat. Prod. Rep., 3,87-121, Mrozik H. et al., 1983, Synthesis of Milbemycins from Avermectins, Tetrahedron Lett., 24, 5333-5336, U.S. Patent No. 4,134,973 and EP 0 677 054, both incorporated herein by reference.
The structure of the avermectins and milbemycins are closely related, e.g., by sharing a complex 16-membered macrocyclic lactone ring. The natural product avermectins are disclosed in U.S. Patent No. 4,310,519 and the 22,23-dihydro avermectin compounds are disclosed in U.S. Patent No. 4,199,569. Mention is also made of U.S. Patent Nos.
4,468,390, 5,824,653, EP 0 007 812 Al, U.K. Patent Specification 1 390 336, EP
916, and New Zealand Patent No. 237 086, inter alia. Naturally occurring milbemycins are described in U.S. Patent No. 3,950,360 as well as in the various references cited in "The Merck Index" 12th ed., S. Budavari, Ed., Merck & Co., Inc. Whitehouse Station, New Jersey (1996). Latidectin is described in the "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, vol. 17, no. 4, pp.
263- 286, (2003). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Patent Nos. 5,077,308, 4,859,657, 4,963,582, 4,855,317, 4,871,719, 4,874,749, 4,427,663, 4,310,519, 4,199,569, 5,055,596, 4,973,711, 4,978,677, 4,920,148 and EP 0 667 054, all incorporated herein by reference.
In one embodiment, the veterinary compositions of the invention may comprise an effective amount of at least one of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin or nemadectin, or a combination thereof. In another embodiment, the invention provides a veterinary composition comprising an effective amount of at least one of abamectin, emamectin, eprinomectin, ivermectin, doramectin or selamectin, or a combination thereof.
In still another embodiment, the veterinary compositions of the invention comprise an effective amount of at least one of ivermectin, milbemectin, milbemycin oxime or moxidectin, or a combination thereof.
In some embodiments, the compositions of the invention may include one or more antinematodal agents including, but not limited to, active agents in the benzimidazoles, imidazothiazoles, tetrahydropyrimidines and the organophosphate class of compounds.
In some embodiments, benzimidazoles including, but not limited to, thiabendazole, cambendazole, parbendazole, oxibendazole, mebendazole, flubendazole, fenbendazole, oxfendazole, albendazole, cyclobendazole, febantel, thiophanate and its o,o-dimethyl analogue may be included in the compositions.
In other embodiments, the compositions of the invention may include an imidazothiazole compounds including, but not limited to, tetramisole, levamisole and butamisole.
In still other embodiments, the compositions of the invention may include tetrahydropyrimidine active agents including, but not limited to, pyrantel, oxantel, and morantel.
Suitable organophosphate active agents include, but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos, mevinphos, monocrotophos, TEPP, and tetrachlorvinphos.
In other embodiments, the compositions may include the antinematodal compounds phenothiazine, piperazine as the neutral compound and in various salt forms, diethylcarbamazine, phenols such as disophenol, arsenicals such as arsenamide, ethanolamines such as bephenium, thenium closylate, and methyridine; cyanine dyes including pyrvinium chloride, pyrvinium pamoate and dithiazanine iodide;
isothiocyanates including bitoscanate, suramin sodium, phthalofyne, and various natural products including, but not limited to, hygromycin B, a-santonin and kainic acid.
In other embodiments, the compositions of the invention may include antitrematodal agents. Suitable antitrematodal agents include, but are not limited to, the miracils such as miracil D and mirasan; praziquantel, clonazepam and its 3-methyl derivative, oltipraz, lucanthone, hycanthone, oxamniquine, amoscanate, niridazole, nitroxynil, various bisphenol compounds known in the art including hexachlorophene, bithionol, bithionol sulfoxide and menichlopholan; various salicylanilide compounds including tribromsalan, oxyclozanide, clioxanide, rafoxanide, nitroxynil, brotianide, bromoxanide and closantel;
triclabendazole, diamfenetide, clorsulon, hetolin and emetine.
Anticestodal compounds may also be advantageously used in the compositions of the invention including, but not limited to, arecoline in various salt forms, bunamidine, niclosamide, nitroscanate, paromomycin, paromomycin 11, praziquantel and epsiprantel.
In yet other embodiments, the compositions of the invention may include other active agents that are effective against arthropod parasites. Suitable active agents include, but are not limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methoxychlor, toxaphene, bromophos, bromophos-ethyl, carbophenothion, chlorfenvinphos, chlorpyrifos, crotoxyphos, cythioate, diazinon, dichlorenthionõ diemthoate, dioxathion, ethion, famphur, fenitrothion, fenthion, fospirate, iodofenphos, malathion, naled, phosalone, phosmet, phoxim, propetamphos, ronnel, stirofos, allethrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, flucythrinate, permethrin, phenothrin, pyrethrins, resmethrin, benzyl benzoate, carbon disulfide, crotamiton, diflubenzuron, diphenylamine, disulfiram, isobornyl thiocyanato acetate, methoprene, monosulfi ram, pirenonylbutoxide, rotenone, triphenyltin acetate, triphenyltin hydroxide, deet, dimethyl phthalate, and the compounds 1,5a,6,9,9a,9b-hexahydro-4a(4H)-dibenzofurancarboxaldehyde (MGK-11), 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-4,7-methano-1H-isoindole-1,3(2H)dione (MGK-264), dipropy1-2,5-pyridinedicarboxylate (MGK-326) and 2-(octylthio)ethanol (MGK-874).
In another embodiment, an antiparasitic agent that can be included in the veterinary compositions of the invention is a biologically active peptide or protein including, but not limited to, depsipeptides other than the compounds of formula (1). These include PF1022A
or analogs thereof and emodepside. These compounds act at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family resulting in the paralysis and death of parasites. In one embodiment of the depsipeptide, the depsipeptide is emodepside (see Wilson et al., Parasitology, Jan. 2003, 126(Pt 1):79-86).
In another embodiment, the compositions of the invention may comprise an active agent from the neonicotinoid class of parasiticides. The neonicotinoids bind and inhibit insect specific nicotinic acetylcholine receptors. In one embodiment, the neonicotinoid insecticidal agent is imidacloprid. Agents of this class are described, for example, in U.S.
Patent No. 4,742,060 or in EP 0 892 060 (both incorporated herein by reference). In another embodiment, the compositions of the invention may comprise nitenpyram, another active agent of the neonicotinoid class of pesticides. The use of nitenpyram for controlling fleas is described in U.S. Patent No. 5,750,548, which is incorporated herein by reference in its entirety.
In certain other embodiments of the invention, the compositions of the invention may include a semicarbazone active agent, such as metaflumizone.
In another embodiment, the compositions of the invention may advantageously include one or more other isoxazoline compounds known in the art, including, but not limited to, afoxolaner, sarolaner and fluralaner. This class of active agents are described in U57,964,204, US 8410153, WO 2014/036056, US 2010/0254960 Al, U52011/0159107, U52012/0309620, U52012/0030841, U52010/0069247, WO 2007/125984, WO
2012/086462, US 8318757, US 8466115, US 8618126, US 8822466, U58383659, U58853186, US 2011/0144349, US 8,053,452; US 8952175, US 2010/0254959, US
2011/152081, WO 2007/075459 and US 2009/0133319, WO 2009/025983 and US
8513431, WO 2009/003075 and US 2010/0173948, WO 2008/150393, WO 2008/154528 and US 8623875, WO 2010/003877 and US 8597688, WO 2010/003923 and US
8563474, WO 2009/045999 and US 8367584, WO 2009/126668 and US 8546618, WO
2009/051956, WO 2012/089623, WO 2012/089622, US 8,119,671; US 7,947,715; WO
2102/120135, WO 2012/107533, WO 2011/157748, US 2011/0245274, US
2011/0245239, US 2012/0232026, US 2012/0077765, US 2012/0035122, US
2011/0251247, W02011/154433, W02011/154434, US 2012/0238517, US
2011/0166193, WO 2011/104088, WO 2011/104087, WO 2011/104089, US 2012/015946, US 2009/0143410, WO 2007/123855A2, US 2011/0118212, U57951828 & U57662972, US 2010/0137372 Al, US 2010/0179194A2, US 2011/0086886 A2, US 2011/0059988 Al, US 201 0/01791 95 Al, US 7897630, and U.S. 7951828, all of which are incorporated herein by reference in their entirety.
In another embodiment of the invention, nodulisporic acid and its derivatives may be added to the compositions of the invention. These compounds are used to treat or prevent infections in humans and animals and are described, for example, in U.S. Patent No. 5,399,582, 5,962,499, 6,221,894 and 6,399,786, all of which are hereby incorporated by reference in their entirety. The compositions may include one or more of the known nodulisporic acid derivatives in the art, including all stereoisomers, such as those described in the literature cited above.
In another embodiment, anthelmintic compounds of the amino acetonitrile class (AAD) of compounds such as monepantel (ZOLVIX) and the like may be added to the compositions of the invention. These compounds are described, for example, in US 7,084,280 to Ducray et al. (incorporated herein by reference); Sager et al., Veterinary Parasitology, 2009, 159, 49-54; Kaminsky et al., Nature vol. 452, 13 March 2008, 176-181.
The compositions of the invention may also include aryloazol-2-ylcyanoethylamino compounds such as those described in US Patent No. 8,088,801 to Soil et al., which is incorporated herein by reference, and thioamide derivatives of these compounds, as described in U.S. Patent No. 7,964,621 to Le Hir de Fallois, which is also incorporated herein by reference. Aryloazol-2-ylcyanoethylamino active agents, which are systemically-acting against endoparasites, may be used in the veterinary compositions of the invention.
The compositions of the invention may also include paraherquamide compounds and derivatives of these compounds, including derquantel (see Ostlind et al., Research in Veterinary Science, 1990, 48, 260-61; and Ostlind et al., Medical and Veterinary Entomology, 1997, 11,407-408). The paraherquamide family of compounds is a known class of compounds that include a spirodioxepino indole core with activity against certain parasites (see Tett. Lett. 1981, 22, 135; J. Antibiotics 1990, 43, 1380, and J. Antibiotics 1991, 44, 492). In addition, the structurally related marcfortine family of compounds, such as marcfortines A-C, are also known and may be combined with the formulations of the invention (see J. Chem. Soc. ¨ Chem. Comm. 1980, 601 and Tet. Lett. 1981, 22, 1977).
Further references to the paraherquamide derivatives can be found, for example, in WO
91/09961, WO 92/22555, WO 97/03988, WO 01/076370, WO 09/004432 and US
2010/0197624, U.S. Patent 5,703,078 and U.S. Patent 5,750,695, all of which are hereby incorporated by reference in their entirety.
In another embodiment of the invention, the compositions may include a spinosyn active agent produced by the soil actinomycete Saccharopolyspora spinosa (see, for example Salgado V.L. and Sparks T.C., "The Spinosyns: Chemistry, Biochemistry, Mode of Action, and Resistance," in Comprehensive Molecular Insect Science, vol. 6, pp. 137-173, 2005) or a semi-synthetic spinosoid active agent. The spinosyns are typically referred to as factors or components A, B, C, D, E, F, G, H, J, K, L, M, N, 0, P, Q, R, S, T, U, V, W, or Y, and any of these components, or a combination thereof, may be used in the compositions of the invention. The spinosyn compound may be a 5,6,5-tricylic ring system, fused to a 12-membered macro cyclic lactone, a neutral sugar (rhamnose), and an amino sugar (forosamine). These and other natural spinosyn compounds, including 21-butenyl spinosyn produced by Saccharopolyspora pagona, which may be used in the compositions of the invention, may be produced via fermentation by conventional techniques known in the art. Other spinosyn compounds that may be used in the compositions of the invention are disclosed in U.S. Patent Nos. 5,496,931;
5,670,364;
5,591,606; 5,571,901; 5,202,242; 5,767,253; 5,840,861; 5,670,486; 5,631,155 and 6,001,981, all incorporated by reference herein in their entirety. The spinosyn compounds may include, but are not limited to, spinosyn A, spinosyn D, spinosad, spinetoram, or combinations thereof. Spinosad is a combination of spinosyn A and spinosyn D, and spinetoram is a combination of 3'-ethoxy-5,6-dihydro spinosyn J and 3'-ethoxy spinosyn L.
In general, additional active agents (other than fipronil and an IGR) are included in the dosage units of the invention in an amount of between about 0.1 lig and about 1000 mg.
Typically, the active agent may be included in an amount of about 10 lig to about 500 mg, about 10 lig to about 400 mg, about 1 mg to about 300 mg, about 10 mg to about 200 mg or about 10 mg to about 100 mg. More typically the additional active agent will be present in an amount of about 5 mg to about 50 mg in the compositions of the invention.
The concentration of the additional active agent in the compositions of the invention will typically be from about 0.01% to about 30% (w/w) depending on the potency of the active agent. In certain embodiments for very potent active agents including, but not limited to a macrocyclic lactone active agent, the concentration of the active agent will typically be from about 0.01% to about 10% (w/w), from about 0.01 to about 1% (w/w), from about 0.01% to about 0.5% (w/w), from about 0.1% to about 0.5% (w/w) or from about 0.01% to about 0.1% (w/w). In other embodiments, the concentration of the active agent will typically be from about 0.1% to about 2% (w/w) or about 0.1% to about 1%
(w/w).
Other components In certain preferred embodiments of the invention, the formulation further comprises one or more antioxidants.
Preferably, the total amount of antioxidant present is from about 0.005 to about 1% (w/v), more preferably from about 0.01 to about 0.05% (w/v) Preferably, the antioxidant is selected from butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate and sodium thiosulphate, and mixtures thereof. More preferably, the antioxidant is butylhydroxyanisole, butylhydroxytoluene, or a mixture thereof.
Salts/esters The active ingredients of the invention can be present as salts or esters, in particular pharmaceutically and veterinarily acceptable salts or esters.
Pharmaceutically acceptable salts of the active ingredients of the invention include suitable acid addition or base salts thereof. A review of suitable pharmaceutical salts may be found in Berge eta!, J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g. hydrohalic acids such as hydrochloride, hydrobromide and hydroiodide, sulphuric acid, phosphoric acid sulphate, bisulphate, hemisulphate, thiocyanate, persulphate and sulphonic acids; with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with amino acids, for example aspartic or glutamic acid;
with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid. Salts which are not pharmaceutically or veterinarily acceptable may still be valuable as intermediates.
Preferred salts include, for example, acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulphonic acids such as methanesulphonate, ethanesulphonate, 2-hydroxyethane sulphonate, camphorsulphonate, 2-naphthalenesulphonate, benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids.
Esters are formed either using organic acids or alcohols/hydroxides, depending on the functional group being esterified. Organic acids include carboxylic acids, such as alkanecarboxylic acids of 1 to 12 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acid, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic;
with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid;
with amino acids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid.
Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide. Alcohols include alkanealcohols of 1-12 carbon atoms which may be unsubstituted or substituted, e.g. by a halogen).
Enantiomers/Tautomers In all aspects of the present invention previously discussed, the invention includes, where appropriate all enantiomers, diastereoisomers and tautomers of the active ingredients of the invention. The person skilled in the art will recognise active ingredients that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics. The corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
Enantiomers are characterised by the absolute configuration of their chiral centres and described by the R- and S-sequencing rules of Cahn, IngoId and Prelog. Such conventions are well known in the art (e.g. see 'Advanced Organic Chemistry', Tcl edition, ed. March, J., John VViley and Sons, New York, 1985).
Active ingredients of the invention containing a chiral centre may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
Stereo and Geometric Isomers Some of the active ingredients of the invention may exist as stereoisomers and/or geometric isomers - e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
The present invention contemplates the use of all the individual stereoisomers and geometric isomers of those active ingredients, and mixtures thereof. The terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
The present invention also includes all suitable isotopic variations of the active ingredient or a pharmaceutically acceptable salt thereof. An isotopic variation of an active ingredient of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2H, 3H, 130, 140, 15N, 170, 180, 31p, 32p, 35s, 18F and 3601, respectively. Certain isotopic variations of the agent and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as 3H or 140 is incorporated, are useful in drug and/or substrate tissue distribution studies.
Tritiated, i.e., 3H, and carbon-14, i.e., 140, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. For example, the invention includes active ingredients where any hydrogen atom has been replaced by a deuterium atom.
Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
Solvates and Polymorphs The present invention also includes solvate forms of the active ingredients of the present invention. The terms used in the claims encompass these forms.
The invention further relates to the active ingredients of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation form the solvents used in the synthetic preparation of such active ingredients.
Veterinarily Acceptable Carrier The formulations of the invention comprise a liquid veterinarily acceptable carrier.
One aspect of the invention relates to formulations where the carrier is an optionally substituted pyrrolidone.
In certain preferred embodiments, the optionally substituted pyrrolidone is selected from 2-pyrrolidone, a 1-(C220-alkyl)-2-pyrrolidone, a 1-(C2_10-alkenyI)-2-pyrrolidone, a 1-(C3-8-cycloalkyl)-2-pyrrolidone, a 1-(Ci_6-hydroxyalkyl)-2-pyrrolidone, a 1-(C1_6-alkoxy-C1_6alkyl)-2-pyrrolidone and 1-benzylpyrrolidone.
In certain more preferred embodiments, the optionally substituted pyrrolidone is selected 1-methylpyrrolidone (NMP), 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s-butyl)-pyrrolidone, 1-(t-butyl)-pyrrolidone, 1-(n-butyl)-pyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-(3-hydroxypropyI)-pyrrolidone, 1-(2-methoxyethyl)-pyrrolidone, 1-(3-methoxpropyI)-pyrrolidone and 1-benzylpyrrolidone, and mixtures thereof.
In certain highly preferred embodiments, the optionally substituted pyrrolidone is N-methylpyrrolidone (NMP).
Another aspect of the invention relates to compositions where the carrier is a glycol ether.
Preferably, the glycol ether is an alkyl ether of ethylene glycol or propylene glycol or an alkyl ether of a polyethylene or polypropylene glycol.
In certain preferred embodiments, the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monoethyl ether (DGME), diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
In other certain preferred embodiments, the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
In one particularly preferred embodiment, the glycol ether is diethylene glycol monoethyl ether (DGME). DGME is available commercially as Transcutole (Gattefosse).
Although it is not preferred, the spot-on formulation may optionally comprise water, in particular in a proportion of form 0 to 30% (volume per unit volume, V/V), in particular from 0 to 5%.
The formulations for topical application according to the invention are typically prepared by simple mixing of the active materials with the veterinarily acceptable carrier, followed by addition of any other ingredients or adjuvants (e.g. antioxidants).
The formulations according to the invention are primarily intended for pets, in particular cats and dogs, and are generally applied by being deposited onto the skin ("spot-on" or "pour-on" application).
The formulation according to the invention may be in the form of a concentrated emulsion, suspension or solution. Preferably, the formulation is a solution.
Spot-on Formulations In one preferred embodiment of the invention, the formulation is in the form of a spot-on formulation. Spot-on formulations are applied to a localized area of the skin, typically an area of less than 10 cm2, more typically between 5 and 10 cm2. Typically, the spot-on formulation is applied two points, preferably localized between the animal's shoulders.
Once deposited, the active ingredients diffuse over the animal's entire body.
Typically, the volume of spot-on formulation applied may be from about 0.3 to 5 ml, preferably about 0.5 ml for cats, and from about 0.3 to 5 ml for dogs, according to the weight of the animal.
Pour-on Formulations In an alternative, but less preferred embodiment, the formulation of the invention is in the form of a pour-on formulation.
Pour-on formulations are typically poured along the dorsal midline of the animal (usually livestock animals). The volume of pour-on formulation applied is typically greater than that for a spot-on formulation and is generally in the order of about 5 ml to about 50 ml, or about 10 ml to about 100 ml, according to the weight of the animal.
Efficacy Formulations of the invention have applications in the treatment and prevention of parasitoses having pathogenic consequences. More specifically, the formulations are for use in controlling ectoparasites, in particular ticks and/or fleas.
Formulations according to the invention, in particular those for spot-on application, have proven to be extremely effective for the very long-lasting treatment of fleas on mammals, and, in particular, small mammals such as cats and dogs.
The very high efficacy of the formulations according to the invention implies not only high immediate efficacy but also very long-lasting efficacy after the animal has been treated.
For the purposes of the present invention, the term flea is understood to refer to all the usual or accidental species of parasitic flea of the order Siphonaptera, and in particular the species Ctenocephalides, in particular C. fells and C. canis, rat fleas (Xenopsylla cheopis) and human fleas (Pulex irritans).
The formulations of the invention are effective against ectoparasites such as insects or arachnids including those of the genera Ctenocephalides, Rhipicephalus, Dermacentor, lxodes, Boophilus, Ambylomma, Haemaphysalis, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Haematopinus, Solenoptes, Trichodectes, and Felicola.
In another embodiment for the treatment against ectoparasites, the ectoparasite is from the genera Ctenocephalides, Rhipicephalus, Dermacentor, lxodes and/or Boophilus. The ectoparasites treated include but are not limited to fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. Specific examples include but are not limited to cat and dog fleas (Ctenocephalides fells, Ctenocephalides spp. and the like), ticks (Rhipicephalus spp., lxodes spp., Dermacentor spp., Amblyoma spp. and the like), and mites (Demodex spp., Sarcoptes spp., Otodectes spp. and the like), lice (Trichodectes spp., Cheyletiella spp., Lignonathus spp., and the like), mosquitoes (Aedes spp., Culex spp., Anopheles spp., and the like) and flies (Hematobia spp., Musca spp., Stomoxys spp., Dematobia spp., Cochliomyia spp., and the like). In yet another embodiment for the treatment against ectoparasites, the ectoparasite is a flea and/or tick.
Additional examples of ectoparasites that are controlled by the formulations of the invention include but are not limited to the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus; myiases such as Dermatobia hominis (known as Berne in Brazil) and Cochliomyia hominivorax (greenbottle);
sheep myiases such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). Flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly); lice such as Linognathus vitulorum, etc.;
and mites such as Sarcoptes scabici and Psoroptes ovis. The above list is not exhaustive and other ectoparasites are well known in the art to be harmful to animals and humans.
These include, for example migrating dipterous larvae.
Dosage A person of ordinary skill in the art can easily determine an appropriate dose of one of the instant formulations to administer to an animal without undue experimentation.
Typically, a veterinarian will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific active ingredients employed, the metabolic stability and length of action of those active ingredients, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the subject undergoing treatment. The dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
It is preferable for the formulation of the invention to be applied to the animal every two or, preferably, every three months on cats and dogs.
Preferably, the treatment is carried out so as to administer to the animal a dose of from 0.1 to 40 and in particular from 1 to 20 mg/kg of fipronil and a dose of from 0.1 to 40 and in particular 1 to 30 mg/kg of the IGR.
The preferred doses are from 5 to 15 mg/kg for fipronil and from 0.5 to 15 mg/kg or 10 to 20 mg/kg for the IGR.
It is understood that the dosage values which are thus indicated are average values which may vary within a wide range, since, in practice, a formulation having defined doses of fipronil and of the IGR will be administered to animals having relatively different weights.
Consequently, the doses actually applied are often smaller or larger by a factor which may be up to 2, 3 or 4 relative to the preferred dose, without entailling any toxic risk for the animal in the case of an overdose, and while at the same time retaining real efficacy, possibly of shorter duration, in the case of an underdose.
The volume applied may be from about 0.3 to 1 ml, preferably about 0.5 ml for cats, and from about 0.3 to 5 ml for dogs, according to the weight of the animal.
Advantageously, the ready-to-use composition contains a dose of from 0.1 to 40 mg/kg of fipronil, and 0.1 to 40 mg/kg of the IGR.
Preferably, a ready-to-use dosed formulation, in particular one for spot-on application, contains 1 to 20 mg/kg, preferably 2 to 10 mg/kg of fipronil, and from 1 to 30 mg/kg, preferably 2 to 10 mg/kg, or 10 to 20 mg/kg of the IGR.
The present invention is further described by way of the following non-limiting examples and figures, wherein:
Figure 1 shows a plot of the percentage efficacy of four different formulations of fipronil and (s)-methoprene (Treatment Groups 2-5) against fleas in dogs. Further details of the experiment are described in the accompanying examples.
EXAMPLES
Efficacy of four formulations of fipronil and (S)-methoprene against fleas (Ctenocephalides fells) on dogs The efficacy of four different formulations of fipronil and (S)-methoprene was evaluated against adult flea (Ctenocephalidis fells) infestations on dogs when compared to untreated controls. In addition, the effect of the combination on flea egg eclosion was also determined.
Forty-four dogs (22 males and 22 females) were used in the study weighing 5.3 to 13.8 kg.
This study was a negative controlled, single-site, clinical efficacy study using a randomized block design with blocks based on pre-treatment live flea counts within sex.
VVithin blocks, dogs were randomly allocated to one of five treatment groups:
Treatment Group 1: untreated control Treatment Group 2:
Commercial formulation - FRONTLINE Plus Spot-on
NMP). Further details of these studies are set forth in the accompanying examples.
In certain particularly preferred embodiments of the invention, the formulations lack both an organic co-solvent, wherein said organic co-solvent has a boiling point of below 100 C
and a dielectric constant of between 10 and 40, and a crystallisation inhibitor as desribed above.
Thus, in certain particularly preferred embodiments of the invention, the formulations do not contain a crystallisation inhibitor as described above, nor do they contain ethanol, methanol or isopropanol.
In one embodiment, the formulations comprise a crystallisation inhibitor as described above, but do not comprise a co-solvent as described above.
In one embodiment, the formulations comprise a co-solvent as described above, but do not comprise a crystallisation inhibitor as described above.
In certain highly preferred embodiments, the formulations consist essentially of, or consist of, fipronil, an IGR, and a veterinarily acceptable carrier which is an optionally substituted pyrrolidone or a glycol ether, and optionally one or more antioxidants.
In other embodiments, the formulations may contain fipronil, an IGR and one or more additional active agents in a veterinarily acceptable carrier.
Insect Growth Regulators The compositions of the invention contain one or more insect growth regulators (IGRs). In one embodiment, the IGR is a compound which mimics juvenile hormones. Suitable examples include:
azadirachtin (Agridyne);
diofenolan (Ciba Geigy);
fenoxycarb (Ciba Geigy);
hydroprene (Sandoz);
kinoprene (Sandoz);
methoprene (Sandoz);
pyriproxyfen (Sumitomo/Mgk);
tetrahydroazadirachtin (Agridyne); and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridazin-3(2H)-one.
In another embodiment, the IGR is a chitin-synthesis inhibitor. Suitable examples include:
chlorfluazuron (Ishihara Sangyo);
cyromazine (Ciba Geigy);
diflubenzuron (Solvay Duphar);
fluazuron (Ciba Geigy);
flucycloxuron (Solvay Duphar);
flufenoxuron (Cyanamid);
hexaflumuron (Dow Elanco);
lufenuron (Ciba Geigy);
tebufenozide (Rohm & Haas);
teflubenzuron (Cyanamid); and triflumuron (Bayer).
The above compounds are defined by their international common name (The Pesticide Manual, 10th edition, 1994, Ed. Clive Tomlin, Great Britain).
As chitin-synthesis inhibitors, mention may also be made of compounds such as 142,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, 1-(2,6-difluorobenzoyI)-3- (2-fluoro-4-(1,1,2,2-tetrafluoroethoxy)phenylurea and 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-trifluoromethyl)phenylurea. Novaluron (Isagro, Italian company) may also be mentioned as an IGR.
In certain preferred embodiments, the IGR is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoy1)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one In certain highly preferred embodiments, the IGR is methoprene, more preferable S-methoprene.
In certain other embodiments, the IGR is pyriproxyfen.
In certain preferred embodiments, the IGR is present in an amount of from about 1 to about 20 % (w/v).
In certain more preferred embodiments, the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
Fipronil The formulations of the present invention all contain fipronil, the compound known as (1-(2,6-C12-4-CF3phenyI)-3-CN-4-(SO-CF3)-5-NH2pyrazole).
Fipronil and related compounds may be prepared according to one or other of the processes described in patent applications WO-A-87/3781, 93/6089, 94/21606 or European patent application EP-A-0,295,117, or any other process which falls within the competence of a specialist skilled in the art of chemical synthesis.
In certain preferred embodiments of the invention, the fipronil is present in an amount of from about 1 to about 20 % (w/v).
Preferably, the fipronil is present in an amount of from about 5 to about 15 %
(w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
The proportions, by weight, of compounds of fipronil and the IGR are preferably between 80/20 and 20/80.
Additional Active Agents In another embodiment of the invention, one or more macrocyclic lactones, which act as an acaricide, an anthelmintic agent and/or an insecticide, can be included in the compositions of the invention. For the avoidance of doubt, the term "macrocyclic lactone"
as used herein includes both naturally occurring and synthetic or semi-synthetic avermectin and milbemycin compounds.
The macrocyclic lactones that may be used in the compositions of the invention include, but are not limited to, the naturally produced avermectins (e.g. including the components designated as Aia, Aib, A2a, A2b, Bia, Bib, B2a and B2b) and milbemycin compounds, semisynthetic avermectins and milbemycins, avermectin monosaccharide compounds and avermectin aglycone compounds. Examples of macrocyclic lactone compounds that may be used in the compositions include, but are not limited to, abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, ML-1,694,554 and milbemycins including, but not limited to, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin and nemadectin.
Also included are the 5-oxo and 5-oxime derivatives of said avermectins and milbemycins.
The macrocyclic lactone compounds are known in the art and can easily be obtained commercially or through synthesis techniques known in the art. Reference is made to the widely available technical and commercial literature. For avermectins, ivermectin and abamectin, reference may be made, for example, to the work "Ivermectin and Abamectin", 1989, by M.H. Fischer and H. Mrozik, VVilliam C. Campbell, published by Springer Verlag., or Albers-Schonberg et al. (1981), "Avermectins Structure Determination", J.
Am. Chem.
Soc., 103, 4216-4221. For doramectin, "Veterinary Parasitology", vol. 49, No.
1, July 1993, 5-15 may be consulted. For milbemycins, reference may be made, inter alia, to Davies H.G. et al., 1986, "Avermectins and Milbemycins", Nat. Prod. Rep., 3,87-121, Mrozik H. et al., 1983, Synthesis of Milbemycins from Avermectins, Tetrahedron Lett., 24, 5333-5336, U.S. Patent No. 4,134,973 and EP 0 677 054, both incorporated herein by reference.
The structure of the avermectins and milbemycins are closely related, e.g., by sharing a complex 16-membered macrocyclic lactone ring. The natural product avermectins are disclosed in U.S. Patent No. 4,310,519 and the 22,23-dihydro avermectin compounds are disclosed in U.S. Patent No. 4,199,569. Mention is also made of U.S. Patent Nos.
4,468,390, 5,824,653, EP 0 007 812 Al, U.K. Patent Specification 1 390 336, EP
916, and New Zealand Patent No. 237 086, inter alia. Naturally occurring milbemycins are described in U.S. Patent No. 3,950,360 as well as in the various references cited in "The Merck Index" 12th ed., S. Budavari, Ed., Merck & Co., Inc. Whitehouse Station, New Jersey (1996). Latidectin is described in the "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, vol. 17, no. 4, pp.
263- 286, (2003). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Patent Nos. 5,077,308, 4,859,657, 4,963,582, 4,855,317, 4,871,719, 4,874,749, 4,427,663, 4,310,519, 4,199,569, 5,055,596, 4,973,711, 4,978,677, 4,920,148 and EP 0 667 054, all incorporated herein by reference.
In one embodiment, the veterinary compositions of the invention may comprise an effective amount of at least one of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin or nemadectin, or a combination thereof. In another embodiment, the invention provides a veterinary composition comprising an effective amount of at least one of abamectin, emamectin, eprinomectin, ivermectin, doramectin or selamectin, or a combination thereof.
In still another embodiment, the veterinary compositions of the invention comprise an effective amount of at least one of ivermectin, milbemectin, milbemycin oxime or moxidectin, or a combination thereof.
In some embodiments, the compositions of the invention may include one or more antinematodal agents including, but not limited to, active agents in the benzimidazoles, imidazothiazoles, tetrahydropyrimidines and the organophosphate class of compounds.
In some embodiments, benzimidazoles including, but not limited to, thiabendazole, cambendazole, parbendazole, oxibendazole, mebendazole, flubendazole, fenbendazole, oxfendazole, albendazole, cyclobendazole, febantel, thiophanate and its o,o-dimethyl analogue may be included in the compositions.
In other embodiments, the compositions of the invention may include an imidazothiazole compounds including, but not limited to, tetramisole, levamisole and butamisole.
In still other embodiments, the compositions of the invention may include tetrahydropyrimidine active agents including, but not limited to, pyrantel, oxantel, and morantel.
Suitable organophosphate active agents include, but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos, mevinphos, monocrotophos, TEPP, and tetrachlorvinphos.
In other embodiments, the compositions may include the antinematodal compounds phenothiazine, piperazine as the neutral compound and in various salt forms, diethylcarbamazine, phenols such as disophenol, arsenicals such as arsenamide, ethanolamines such as bephenium, thenium closylate, and methyridine; cyanine dyes including pyrvinium chloride, pyrvinium pamoate and dithiazanine iodide;
isothiocyanates including bitoscanate, suramin sodium, phthalofyne, and various natural products including, but not limited to, hygromycin B, a-santonin and kainic acid.
In other embodiments, the compositions of the invention may include antitrematodal agents. Suitable antitrematodal agents include, but are not limited to, the miracils such as miracil D and mirasan; praziquantel, clonazepam and its 3-methyl derivative, oltipraz, lucanthone, hycanthone, oxamniquine, amoscanate, niridazole, nitroxynil, various bisphenol compounds known in the art including hexachlorophene, bithionol, bithionol sulfoxide and menichlopholan; various salicylanilide compounds including tribromsalan, oxyclozanide, clioxanide, rafoxanide, nitroxynil, brotianide, bromoxanide and closantel;
triclabendazole, diamfenetide, clorsulon, hetolin and emetine.
Anticestodal compounds may also be advantageously used in the compositions of the invention including, but not limited to, arecoline in various salt forms, bunamidine, niclosamide, nitroscanate, paromomycin, paromomycin 11, praziquantel and epsiprantel.
In yet other embodiments, the compositions of the invention may include other active agents that are effective against arthropod parasites. Suitable active agents include, but are not limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methoxychlor, toxaphene, bromophos, bromophos-ethyl, carbophenothion, chlorfenvinphos, chlorpyrifos, crotoxyphos, cythioate, diazinon, dichlorenthionõ diemthoate, dioxathion, ethion, famphur, fenitrothion, fenthion, fospirate, iodofenphos, malathion, naled, phosalone, phosmet, phoxim, propetamphos, ronnel, stirofos, allethrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, flucythrinate, permethrin, phenothrin, pyrethrins, resmethrin, benzyl benzoate, carbon disulfide, crotamiton, diflubenzuron, diphenylamine, disulfiram, isobornyl thiocyanato acetate, methoprene, monosulfi ram, pirenonylbutoxide, rotenone, triphenyltin acetate, triphenyltin hydroxide, deet, dimethyl phthalate, and the compounds 1,5a,6,9,9a,9b-hexahydro-4a(4H)-dibenzofurancarboxaldehyde (MGK-11), 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-4,7-methano-1H-isoindole-1,3(2H)dione (MGK-264), dipropy1-2,5-pyridinedicarboxylate (MGK-326) and 2-(octylthio)ethanol (MGK-874).
In another embodiment, an antiparasitic agent that can be included in the veterinary compositions of the invention is a biologically active peptide or protein including, but not limited to, depsipeptides other than the compounds of formula (1). These include PF1022A
or analogs thereof and emodepside. These compounds act at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family resulting in the paralysis and death of parasites. In one embodiment of the depsipeptide, the depsipeptide is emodepside (see Wilson et al., Parasitology, Jan. 2003, 126(Pt 1):79-86).
In another embodiment, the compositions of the invention may comprise an active agent from the neonicotinoid class of parasiticides. The neonicotinoids bind and inhibit insect specific nicotinic acetylcholine receptors. In one embodiment, the neonicotinoid insecticidal agent is imidacloprid. Agents of this class are described, for example, in U.S.
Patent No. 4,742,060 or in EP 0 892 060 (both incorporated herein by reference). In another embodiment, the compositions of the invention may comprise nitenpyram, another active agent of the neonicotinoid class of pesticides. The use of nitenpyram for controlling fleas is described in U.S. Patent No. 5,750,548, which is incorporated herein by reference in its entirety.
In certain other embodiments of the invention, the compositions of the invention may include a semicarbazone active agent, such as metaflumizone.
In another embodiment, the compositions of the invention may advantageously include one or more other isoxazoline compounds known in the art, including, but not limited to, afoxolaner, sarolaner and fluralaner. This class of active agents are described in U57,964,204, US 8410153, WO 2014/036056, US 2010/0254960 Al, U52011/0159107, U52012/0309620, U52012/0030841, U52010/0069247, WO 2007/125984, WO
2012/086462, US 8318757, US 8466115, US 8618126, US 8822466, U58383659, U58853186, US 2011/0144349, US 8,053,452; US 8952175, US 2010/0254959, US
2011/152081, WO 2007/075459 and US 2009/0133319, WO 2009/025983 and US
8513431, WO 2009/003075 and US 2010/0173948, WO 2008/150393, WO 2008/154528 and US 8623875, WO 2010/003877 and US 8597688, WO 2010/003923 and US
8563474, WO 2009/045999 and US 8367584, WO 2009/126668 and US 8546618, WO
2009/051956, WO 2012/089623, WO 2012/089622, US 8,119,671; US 7,947,715; WO
2102/120135, WO 2012/107533, WO 2011/157748, US 2011/0245274, US
2011/0245239, US 2012/0232026, US 2012/0077765, US 2012/0035122, US
2011/0251247, W02011/154433, W02011/154434, US 2012/0238517, US
2011/0166193, WO 2011/104088, WO 2011/104087, WO 2011/104089, US 2012/015946, US 2009/0143410, WO 2007/123855A2, US 2011/0118212, U57951828 & U57662972, US 2010/0137372 Al, US 2010/0179194A2, US 2011/0086886 A2, US 2011/0059988 Al, US 201 0/01791 95 Al, US 7897630, and U.S. 7951828, all of which are incorporated herein by reference in their entirety.
In another embodiment of the invention, nodulisporic acid and its derivatives may be added to the compositions of the invention. These compounds are used to treat or prevent infections in humans and animals and are described, for example, in U.S. Patent No. 5,399,582, 5,962,499, 6,221,894 and 6,399,786, all of which are hereby incorporated by reference in their entirety. The compositions may include one or more of the known nodulisporic acid derivatives in the art, including all stereoisomers, such as those described in the literature cited above.
In another embodiment, anthelmintic compounds of the amino acetonitrile class (AAD) of compounds such as monepantel (ZOLVIX) and the like may be added to the compositions of the invention. These compounds are described, for example, in US 7,084,280 to Ducray et al. (incorporated herein by reference); Sager et al., Veterinary Parasitology, 2009, 159, 49-54; Kaminsky et al., Nature vol. 452, 13 March 2008, 176-181.
The compositions of the invention may also include aryloazol-2-ylcyanoethylamino compounds such as those described in US Patent No. 8,088,801 to Soil et al., which is incorporated herein by reference, and thioamide derivatives of these compounds, as described in U.S. Patent No. 7,964,621 to Le Hir de Fallois, which is also incorporated herein by reference. Aryloazol-2-ylcyanoethylamino active agents, which are systemically-acting against endoparasites, may be used in the veterinary compositions of the invention.
The compositions of the invention may also include paraherquamide compounds and derivatives of these compounds, including derquantel (see Ostlind et al., Research in Veterinary Science, 1990, 48, 260-61; and Ostlind et al., Medical and Veterinary Entomology, 1997, 11,407-408). The paraherquamide family of compounds is a known class of compounds that include a spirodioxepino indole core with activity against certain parasites (see Tett. Lett. 1981, 22, 135; J. Antibiotics 1990, 43, 1380, and J. Antibiotics 1991, 44, 492). In addition, the structurally related marcfortine family of compounds, such as marcfortines A-C, are also known and may be combined with the formulations of the invention (see J. Chem. Soc. ¨ Chem. Comm. 1980, 601 and Tet. Lett. 1981, 22, 1977).
Further references to the paraherquamide derivatives can be found, for example, in WO
91/09961, WO 92/22555, WO 97/03988, WO 01/076370, WO 09/004432 and US
2010/0197624, U.S. Patent 5,703,078 and U.S. Patent 5,750,695, all of which are hereby incorporated by reference in their entirety.
In another embodiment of the invention, the compositions may include a spinosyn active agent produced by the soil actinomycete Saccharopolyspora spinosa (see, for example Salgado V.L. and Sparks T.C., "The Spinosyns: Chemistry, Biochemistry, Mode of Action, and Resistance," in Comprehensive Molecular Insect Science, vol. 6, pp. 137-173, 2005) or a semi-synthetic spinosoid active agent. The spinosyns are typically referred to as factors or components A, B, C, D, E, F, G, H, J, K, L, M, N, 0, P, Q, R, S, T, U, V, W, or Y, and any of these components, or a combination thereof, may be used in the compositions of the invention. The spinosyn compound may be a 5,6,5-tricylic ring system, fused to a 12-membered macro cyclic lactone, a neutral sugar (rhamnose), and an amino sugar (forosamine). These and other natural spinosyn compounds, including 21-butenyl spinosyn produced by Saccharopolyspora pagona, which may be used in the compositions of the invention, may be produced via fermentation by conventional techniques known in the art. Other spinosyn compounds that may be used in the compositions of the invention are disclosed in U.S. Patent Nos. 5,496,931;
5,670,364;
5,591,606; 5,571,901; 5,202,242; 5,767,253; 5,840,861; 5,670,486; 5,631,155 and 6,001,981, all incorporated by reference herein in their entirety. The spinosyn compounds may include, but are not limited to, spinosyn A, spinosyn D, spinosad, spinetoram, or combinations thereof. Spinosad is a combination of spinosyn A and spinosyn D, and spinetoram is a combination of 3'-ethoxy-5,6-dihydro spinosyn J and 3'-ethoxy spinosyn L.
In general, additional active agents (other than fipronil and an IGR) are included in the dosage units of the invention in an amount of between about 0.1 lig and about 1000 mg.
Typically, the active agent may be included in an amount of about 10 lig to about 500 mg, about 10 lig to about 400 mg, about 1 mg to about 300 mg, about 10 mg to about 200 mg or about 10 mg to about 100 mg. More typically the additional active agent will be present in an amount of about 5 mg to about 50 mg in the compositions of the invention.
The concentration of the additional active agent in the compositions of the invention will typically be from about 0.01% to about 30% (w/w) depending on the potency of the active agent. In certain embodiments for very potent active agents including, but not limited to a macrocyclic lactone active agent, the concentration of the active agent will typically be from about 0.01% to about 10% (w/w), from about 0.01 to about 1% (w/w), from about 0.01% to about 0.5% (w/w), from about 0.1% to about 0.5% (w/w) or from about 0.01% to about 0.1% (w/w). In other embodiments, the concentration of the active agent will typically be from about 0.1% to about 2% (w/w) or about 0.1% to about 1%
(w/w).
Other components In certain preferred embodiments of the invention, the formulation further comprises one or more antioxidants.
Preferably, the total amount of antioxidant present is from about 0.005 to about 1% (w/v), more preferably from about 0.01 to about 0.05% (w/v) Preferably, the antioxidant is selected from butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate and sodium thiosulphate, and mixtures thereof. More preferably, the antioxidant is butylhydroxyanisole, butylhydroxytoluene, or a mixture thereof.
Salts/esters The active ingredients of the invention can be present as salts or esters, in particular pharmaceutically and veterinarily acceptable salts or esters.
Pharmaceutically acceptable salts of the active ingredients of the invention include suitable acid addition or base salts thereof. A review of suitable pharmaceutical salts may be found in Berge eta!, J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g. hydrohalic acids such as hydrochloride, hydrobromide and hydroiodide, sulphuric acid, phosphoric acid sulphate, bisulphate, hemisulphate, thiocyanate, persulphate and sulphonic acids; with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with amino acids, for example aspartic or glutamic acid;
with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid. Salts which are not pharmaceutically or veterinarily acceptable may still be valuable as intermediates.
Preferred salts include, for example, acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulphonic acids such as methanesulphonate, ethanesulphonate, 2-hydroxyethane sulphonate, camphorsulphonate, 2-naphthalenesulphonate, benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids.
Esters are formed either using organic acids or alcohols/hydroxides, depending on the functional group being esterified. Organic acids include carboxylic acids, such as alkanecarboxylic acids of 1 to 12 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acid, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic;
with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid;
with amino acids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid.
Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide. Alcohols include alkanealcohols of 1-12 carbon atoms which may be unsubstituted or substituted, e.g. by a halogen).
Enantiomers/Tautomers In all aspects of the present invention previously discussed, the invention includes, where appropriate all enantiomers, diastereoisomers and tautomers of the active ingredients of the invention. The person skilled in the art will recognise active ingredients that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics. The corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
Enantiomers are characterised by the absolute configuration of their chiral centres and described by the R- and S-sequencing rules of Cahn, IngoId and Prelog. Such conventions are well known in the art (e.g. see 'Advanced Organic Chemistry', Tcl edition, ed. March, J., John VViley and Sons, New York, 1985).
Active ingredients of the invention containing a chiral centre may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
Stereo and Geometric Isomers Some of the active ingredients of the invention may exist as stereoisomers and/or geometric isomers - e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
The present invention contemplates the use of all the individual stereoisomers and geometric isomers of those active ingredients, and mixtures thereof. The terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
The present invention also includes all suitable isotopic variations of the active ingredient or a pharmaceutically acceptable salt thereof. An isotopic variation of an active ingredient of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2H, 3H, 130, 140, 15N, 170, 180, 31p, 32p, 35s, 18F and 3601, respectively. Certain isotopic variations of the agent and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as 3H or 140 is incorporated, are useful in drug and/or substrate tissue distribution studies.
Tritiated, i.e., 3H, and carbon-14, i.e., 140, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. For example, the invention includes active ingredients where any hydrogen atom has been replaced by a deuterium atom.
Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
Solvates and Polymorphs The present invention also includes solvate forms of the active ingredients of the present invention. The terms used in the claims encompass these forms.
The invention further relates to the active ingredients of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation form the solvents used in the synthetic preparation of such active ingredients.
Veterinarily Acceptable Carrier The formulations of the invention comprise a liquid veterinarily acceptable carrier.
One aspect of the invention relates to formulations where the carrier is an optionally substituted pyrrolidone.
In certain preferred embodiments, the optionally substituted pyrrolidone is selected from 2-pyrrolidone, a 1-(C220-alkyl)-2-pyrrolidone, a 1-(C2_10-alkenyI)-2-pyrrolidone, a 1-(C3-8-cycloalkyl)-2-pyrrolidone, a 1-(Ci_6-hydroxyalkyl)-2-pyrrolidone, a 1-(C1_6-alkoxy-C1_6alkyl)-2-pyrrolidone and 1-benzylpyrrolidone.
In certain more preferred embodiments, the optionally substituted pyrrolidone is selected 1-methylpyrrolidone (NMP), 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s-butyl)-pyrrolidone, 1-(t-butyl)-pyrrolidone, 1-(n-butyl)-pyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-(3-hydroxypropyI)-pyrrolidone, 1-(2-methoxyethyl)-pyrrolidone, 1-(3-methoxpropyI)-pyrrolidone and 1-benzylpyrrolidone, and mixtures thereof.
In certain highly preferred embodiments, the optionally substituted pyrrolidone is N-methylpyrrolidone (NMP).
Another aspect of the invention relates to compositions where the carrier is a glycol ether.
Preferably, the glycol ether is an alkyl ether of ethylene glycol or propylene glycol or an alkyl ether of a polyethylene or polypropylene glycol.
In certain preferred embodiments, the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monoethyl ether (DGME), diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
In other certain preferred embodiments, the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
In one particularly preferred embodiment, the glycol ether is diethylene glycol monoethyl ether (DGME). DGME is available commercially as Transcutole (Gattefosse).
Although it is not preferred, the spot-on formulation may optionally comprise water, in particular in a proportion of form 0 to 30% (volume per unit volume, V/V), in particular from 0 to 5%.
The formulations for topical application according to the invention are typically prepared by simple mixing of the active materials with the veterinarily acceptable carrier, followed by addition of any other ingredients or adjuvants (e.g. antioxidants).
The formulations according to the invention are primarily intended for pets, in particular cats and dogs, and are generally applied by being deposited onto the skin ("spot-on" or "pour-on" application).
The formulation according to the invention may be in the form of a concentrated emulsion, suspension or solution. Preferably, the formulation is a solution.
Spot-on Formulations In one preferred embodiment of the invention, the formulation is in the form of a spot-on formulation. Spot-on formulations are applied to a localized area of the skin, typically an area of less than 10 cm2, more typically between 5 and 10 cm2. Typically, the spot-on formulation is applied two points, preferably localized between the animal's shoulders.
Once deposited, the active ingredients diffuse over the animal's entire body.
Typically, the volume of spot-on formulation applied may be from about 0.3 to 5 ml, preferably about 0.5 ml for cats, and from about 0.3 to 5 ml for dogs, according to the weight of the animal.
Pour-on Formulations In an alternative, but less preferred embodiment, the formulation of the invention is in the form of a pour-on formulation.
Pour-on formulations are typically poured along the dorsal midline of the animal (usually livestock animals). The volume of pour-on formulation applied is typically greater than that for a spot-on formulation and is generally in the order of about 5 ml to about 50 ml, or about 10 ml to about 100 ml, according to the weight of the animal.
Efficacy Formulations of the invention have applications in the treatment and prevention of parasitoses having pathogenic consequences. More specifically, the formulations are for use in controlling ectoparasites, in particular ticks and/or fleas.
Formulations according to the invention, in particular those for spot-on application, have proven to be extremely effective for the very long-lasting treatment of fleas on mammals, and, in particular, small mammals such as cats and dogs.
The very high efficacy of the formulations according to the invention implies not only high immediate efficacy but also very long-lasting efficacy after the animal has been treated.
For the purposes of the present invention, the term flea is understood to refer to all the usual or accidental species of parasitic flea of the order Siphonaptera, and in particular the species Ctenocephalides, in particular C. fells and C. canis, rat fleas (Xenopsylla cheopis) and human fleas (Pulex irritans).
The formulations of the invention are effective against ectoparasites such as insects or arachnids including those of the genera Ctenocephalides, Rhipicephalus, Dermacentor, lxodes, Boophilus, Ambylomma, Haemaphysalis, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Haematopinus, Solenoptes, Trichodectes, and Felicola.
In another embodiment for the treatment against ectoparasites, the ectoparasite is from the genera Ctenocephalides, Rhipicephalus, Dermacentor, lxodes and/or Boophilus. The ectoparasites treated include but are not limited to fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. Specific examples include but are not limited to cat and dog fleas (Ctenocephalides fells, Ctenocephalides spp. and the like), ticks (Rhipicephalus spp., lxodes spp., Dermacentor spp., Amblyoma spp. and the like), and mites (Demodex spp., Sarcoptes spp., Otodectes spp. and the like), lice (Trichodectes spp., Cheyletiella spp., Lignonathus spp., and the like), mosquitoes (Aedes spp., Culex spp., Anopheles spp., and the like) and flies (Hematobia spp., Musca spp., Stomoxys spp., Dematobia spp., Cochliomyia spp., and the like). In yet another embodiment for the treatment against ectoparasites, the ectoparasite is a flea and/or tick.
Additional examples of ectoparasites that are controlled by the formulations of the invention include but are not limited to the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus; myiases such as Dermatobia hominis (known as Berne in Brazil) and Cochliomyia hominivorax (greenbottle);
sheep myiases such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). Flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly); lice such as Linognathus vitulorum, etc.;
and mites such as Sarcoptes scabici and Psoroptes ovis. The above list is not exhaustive and other ectoparasites are well known in the art to be harmful to animals and humans.
These include, for example migrating dipterous larvae.
Dosage A person of ordinary skill in the art can easily determine an appropriate dose of one of the instant formulations to administer to an animal without undue experimentation.
Typically, a veterinarian will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific active ingredients employed, the metabolic stability and length of action of those active ingredients, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the subject undergoing treatment. The dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
It is preferable for the formulation of the invention to be applied to the animal every two or, preferably, every three months on cats and dogs.
Preferably, the treatment is carried out so as to administer to the animal a dose of from 0.1 to 40 and in particular from 1 to 20 mg/kg of fipronil and a dose of from 0.1 to 40 and in particular 1 to 30 mg/kg of the IGR.
The preferred doses are from 5 to 15 mg/kg for fipronil and from 0.5 to 15 mg/kg or 10 to 20 mg/kg for the IGR.
It is understood that the dosage values which are thus indicated are average values which may vary within a wide range, since, in practice, a formulation having defined doses of fipronil and of the IGR will be administered to animals having relatively different weights.
Consequently, the doses actually applied are often smaller or larger by a factor which may be up to 2, 3 or 4 relative to the preferred dose, without entailling any toxic risk for the animal in the case of an overdose, and while at the same time retaining real efficacy, possibly of shorter duration, in the case of an underdose.
The volume applied may be from about 0.3 to 1 ml, preferably about 0.5 ml for cats, and from about 0.3 to 5 ml for dogs, according to the weight of the animal.
Advantageously, the ready-to-use composition contains a dose of from 0.1 to 40 mg/kg of fipronil, and 0.1 to 40 mg/kg of the IGR.
Preferably, a ready-to-use dosed formulation, in particular one for spot-on application, contains 1 to 20 mg/kg, preferably 2 to 10 mg/kg of fipronil, and from 1 to 30 mg/kg, preferably 2 to 10 mg/kg, or 10 to 20 mg/kg of the IGR.
The present invention is further described by way of the following non-limiting examples and figures, wherein:
Figure 1 shows a plot of the percentage efficacy of four different formulations of fipronil and (s)-methoprene (Treatment Groups 2-5) against fleas in dogs. Further details of the experiment are described in the accompanying examples.
EXAMPLES
Efficacy of four formulations of fipronil and (S)-methoprene against fleas (Ctenocephalides fells) on dogs The efficacy of four different formulations of fipronil and (S)-methoprene was evaluated against adult flea (Ctenocephalidis fells) infestations on dogs when compared to untreated controls. In addition, the effect of the combination on flea egg eclosion was also determined.
Forty-four dogs (22 males and 22 females) were used in the study weighing 5.3 to 13.8 kg.
This study was a negative controlled, single-site, clinical efficacy study using a randomized block design with blocks based on pre-treatment live flea counts within sex.
VVithin blocks, dogs were randomly allocated to one of five treatment groups:
Treatment Group 1: untreated control Treatment Group 2:
Commercial formulation - FRONTLINE Plus Spot-on
10% w/v fipronil 9% w/v (S)-methoprene Treatment Group 3:
Topical spot-on 10% w/v fipronil 10% w/v (S)-methoprene QS diethylene glycol monoethyl ether (DGME) Treatment Group 4:
Topical spot-on 10c/o w/v fipronil 10% w/v (S)-methoprene QS N-methyl pyrrolidone (NMP) Treatment Group 5 Topical Spot-on 10% w/v fipronil 10% w/v (S)-methoprene 5% (w/v) polyvinylpyrrolidone (PVP) Kollidon 17 5% (w/v) polysorbate 80 QS diethylene glycol monoethyl ether (DGME) Dogs in Treatment Group 1 were untreated while dogs in Groups 2-5 were each treated on Day 0 with 0.1 mlikg body weight of the appropriate formulation containing fipronil and (S)-methoprene. Each formulation contained 10% w/v fipronil and 10% w/v (S)-methoprene (except in Group 2, in which the formulation contained 10% w/v fipronil and 9% w/v (S)-methoprene) and varied in amount and type of excipients.
Untreated control dogs and dogs in Groups 3 and 4 were infested with 100 adult fleas on Days -1, 7, 14, 21, 28, 35, 42, 49, 56 and 63. Dogs in groups 2 and 5 were infested with fleas on Days -1, 7, 14, 21, 28, 35, 42 and 49. Dogs in Groups 2 and 5 were not infested after D49 because the percent adult flea efficacy fell below 90% for these two groups. For flea infestations, approximately 100 unfed adult C. felis fleas were placed along the lateral midline of each animal from the shoulder to the hip. Dogs were restrained for sufficient time to allow the fleas to penetrate the hair coat.
Fleas were counted and removed by combing approximately 48 hours after treatment or subsequent infestation. Percent efficacy of the formulations as compared to the untreated control group against the adult fleas at each time point was determined.
Flea eggs were collected and incubated in the untreated control dogs and dogs in Groups 2 and 5 on Day 51 and in the untreated control dogs and dogs in Groups 3 and 4 on Day 65. On the day prior to flea egg collection, the cage was prepared for egg collection, and food and water were removed to allow flea eggs to be collected for 24 hours. The eggs were thereafter incubated at 20.7 to 27.5 degrees C and 69 to 99%
relative humidity for 72 hours, and then the hatched larvae were counted.
Efficacy of each formulation in preventing flea egg eclosion as compared to the untreated control group was then determined.
Results and Discussion Flea adulticide activity due to the combination formulations was maintained 90% as follows. The number in the parenthesis is the actual adulticide efficacy at the end of time indicated.
Group 2: 44 days (90.7%) Group 3: 58 days (92.2%) Group 4: 65 days (91.1%) Group 5: 37 days (95.0%) A summary of the flea adulticide efficacy over the time of the study is provided in Table 1 below, and Figure 1.
Table 1:
Table1:: FkmAthtde Pement Efficacy Storiy Day e Flea Count p2 100 100 100 100 997 C.37 7 90.7 68.0 NA En Group 3 100 100 100 100 100 100 100 09.4 92.2 G MAP 4 100 100 100 100 100 100 100 9a.? 99.4 Group 5 09 100 100 ... 09.0 05.0 =F.6.5 =55 4 NA
These results indicate that all the various formulations of fipronil and (S)-methoprene provided excellent efficacy 90%) against adult fleas for at least 35 days, and two formulations were highly effective through at least 58 days.
The percent efficacies (PE) of all four treated groups was greater than or equal to 99.0%
through counts on Day 30.
The PE for FRONTLINE Plus (Treatment Group 2) was 97.7%, 90.7%, and 68.0% on Days 37, 44, and 51, respectively; it received no further infestations.
The PE for Treatment Group 5 was 95.0%, 86.6%, and 56.4% on Days 37, 44, and 51, respectively; it too received no further infestations.
The PE for Treatment Group 3 was 100.0%, 100.0%, 99.4%, 92.2%, and 81.1% on Days 37, 44, 51, 58, and 65, respectively.
The PE for Treatment Group 4 was 100.0%, 100.0%, 99.7%, 99.4%, and 91.1% on Days 37, 44, 51, 58, and 65, respectively.
For all treated groups over all infestation days, the treated and control groups were significantly different at the 5% significance level (p 0.034; see Table 1).
In particular, it is noted that the spot-on formulations used in Groups 3 and 4 (both of which lack a crystallisation inhibitor) exhibit surprisingly good duration of efficacy compared to Groups 2 (FRONTLINE Plus) and Group 5 (which contains PVP as a crystallisation inhibitor).
The results of the analysis of the proportion of eggs that hatched into larvae on Days 54 and 68 (following collections on Days 51 and 65, respectively) are presented in Table 2 below.
Table 2: Analysis of Proportion of Eggs that Hatch into Larvae Study Treatment No, of Proportion Percent PA/MI..1W
day z Group Dogs Hatched' Red action6 54 1 8 0.60 (4801800) NA' 54 2 a 0.05 (31/660) 92,2 <,001 54 5 i 8 0 02 (18/800) 96_3 1 <,001 68 1 g a64 (509/800) NA
68 3 5 0,12 (40/321) 80,4 <,001 0.03 (15/544) 95.6 <.001 1The proportion of eggs that hatched into larvae in the treated groups were compared with the proportion in the Untreated Control group;
2Day that egg hatch was counted; eggs were collected on Days 51 and 65, respectively, 48 hours after infestation;
4The proportion of eggs that hatched into larvae. The actual number that hatched into larvae over the total number of eggs incubated are listed in the parentheses;
5Percent reduction= [(C-T)/C]xl 00, where T and Care the proportion of eggs that hatched into larvae for the indicated treated group and the Untreated Control group, respectively;
6(Two-sided) probability value testing the hypothesis that the population proportion of the indicated treated group was not equal to the population proportion of the Untreated Control group;
'Percent reduction with respect to itself.
Eggs were collected from the groups Untreated Control, FRONTLINE Plus, and Treatment Group 5 on Day 54. Following incubation, the proportion of eggs that hatched in the two treated groups was compared with the Untreated Control group. The percent reduction of eggs that hatched into larvae was 92.2% and 96.3% for FRONTLINE
Plus and Treatment Group 5, respectively. For both, the population means of the treated and Untreated Control groups were significantly different (p < 0.001 for both; see Table 2).
Eggs were collected from the groups Untreated Control, Treatment Group 3 and Treatment Group 4 on Day 65. Following incubation, the proportion of eggs that hatched in the two treated groups was compared with the Untreated Control group. The percent reduction of eggs that hatched into larvae was 80.4% and 95.6% for Treatment Groups 3 and Treatment Group 4, respectively.
For both, the population means of the treated and Untreated Control groups were significantly different (p < 0.001 for both).
Conclusion In conclusion, all four fipronil:(S)-methoprene formulations provided excellent efficacy against adult flea infestations on dogs and prevented flea egg eclosion for several weeks past the single treatment. All formulations provided flea adulticide activity of 90% for at least 35 days and one formulation was highly effective up through 65 days.
Moreover, the formulations used in Treatment Group 4 (NM P alone) and Group 3 (DGME alone) were particularly effective.
The results show that fipronil and (S)-methoprene can be formulated in a variety of solvents and excipients and provide excellent activity for several weeks against adult fleas and in the prevention of flea egg eclosion.
The invention is further described with reference to the following numbered paragraphs.
1. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
2. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain ethanol, methanol or isopropanol.
3. A topical formulation according to paragraph 1 or paragraph 2 which does not contain a crystallisation inhibitor.
4. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain a crystallisation inhibitor.
5. A topical formulation according to paragraph 3 or paragraph 4 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
6. A topical formulation according to paragraph 4 or paragraph 5 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C
and a dielectric constant of between 10 and 40.
7. A topical formulation according to paragraph 4 or paragraph 5 wherein said formulation does not contain ethanol, methanol or isopropanol.
8. A topical formulation according to any preceding paragraph wherein the IGR is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
9. A topical formulation according to any preceding paragraph wherein the IGR is methoprene.
10. A topical formulation according to any one of paragraphs 1 to 8 wherein the IGR is pyriproxyfen.
Topical spot-on 10% w/v fipronil 10% w/v (S)-methoprene QS diethylene glycol monoethyl ether (DGME) Treatment Group 4:
Topical spot-on 10c/o w/v fipronil 10% w/v (S)-methoprene QS N-methyl pyrrolidone (NMP) Treatment Group 5 Topical Spot-on 10% w/v fipronil 10% w/v (S)-methoprene 5% (w/v) polyvinylpyrrolidone (PVP) Kollidon 17 5% (w/v) polysorbate 80 QS diethylene glycol monoethyl ether (DGME) Dogs in Treatment Group 1 were untreated while dogs in Groups 2-5 were each treated on Day 0 with 0.1 mlikg body weight of the appropriate formulation containing fipronil and (S)-methoprene. Each formulation contained 10% w/v fipronil and 10% w/v (S)-methoprene (except in Group 2, in which the formulation contained 10% w/v fipronil and 9% w/v (S)-methoprene) and varied in amount and type of excipients.
Untreated control dogs and dogs in Groups 3 and 4 were infested with 100 adult fleas on Days -1, 7, 14, 21, 28, 35, 42, 49, 56 and 63. Dogs in groups 2 and 5 were infested with fleas on Days -1, 7, 14, 21, 28, 35, 42 and 49. Dogs in Groups 2 and 5 were not infested after D49 because the percent adult flea efficacy fell below 90% for these two groups. For flea infestations, approximately 100 unfed adult C. felis fleas were placed along the lateral midline of each animal from the shoulder to the hip. Dogs were restrained for sufficient time to allow the fleas to penetrate the hair coat.
Fleas were counted and removed by combing approximately 48 hours after treatment or subsequent infestation. Percent efficacy of the formulations as compared to the untreated control group against the adult fleas at each time point was determined.
Flea eggs were collected and incubated in the untreated control dogs and dogs in Groups 2 and 5 on Day 51 and in the untreated control dogs and dogs in Groups 3 and 4 on Day 65. On the day prior to flea egg collection, the cage was prepared for egg collection, and food and water were removed to allow flea eggs to be collected for 24 hours. The eggs were thereafter incubated at 20.7 to 27.5 degrees C and 69 to 99%
relative humidity for 72 hours, and then the hatched larvae were counted.
Efficacy of each formulation in preventing flea egg eclosion as compared to the untreated control group was then determined.
Results and Discussion Flea adulticide activity due to the combination formulations was maintained 90% as follows. The number in the parenthesis is the actual adulticide efficacy at the end of time indicated.
Group 2: 44 days (90.7%) Group 3: 58 days (92.2%) Group 4: 65 days (91.1%) Group 5: 37 days (95.0%) A summary of the flea adulticide efficacy over the time of the study is provided in Table 1 below, and Figure 1.
Table 1:
Table1:: FkmAthtde Pement Efficacy Storiy Day e Flea Count p2 100 100 100 100 997 C.37 7 90.7 68.0 NA En Group 3 100 100 100 100 100 100 100 09.4 92.2 G MAP 4 100 100 100 100 100 100 100 9a.? 99.4 Group 5 09 100 100 ... 09.0 05.0 =F.6.5 =55 4 NA
These results indicate that all the various formulations of fipronil and (S)-methoprene provided excellent efficacy 90%) against adult fleas for at least 35 days, and two formulations were highly effective through at least 58 days.
The percent efficacies (PE) of all four treated groups was greater than or equal to 99.0%
through counts on Day 30.
The PE for FRONTLINE Plus (Treatment Group 2) was 97.7%, 90.7%, and 68.0% on Days 37, 44, and 51, respectively; it received no further infestations.
The PE for Treatment Group 5 was 95.0%, 86.6%, and 56.4% on Days 37, 44, and 51, respectively; it too received no further infestations.
The PE for Treatment Group 3 was 100.0%, 100.0%, 99.4%, 92.2%, and 81.1% on Days 37, 44, 51, 58, and 65, respectively.
The PE for Treatment Group 4 was 100.0%, 100.0%, 99.7%, 99.4%, and 91.1% on Days 37, 44, 51, 58, and 65, respectively.
For all treated groups over all infestation days, the treated and control groups were significantly different at the 5% significance level (p 0.034; see Table 1).
In particular, it is noted that the spot-on formulations used in Groups 3 and 4 (both of which lack a crystallisation inhibitor) exhibit surprisingly good duration of efficacy compared to Groups 2 (FRONTLINE Plus) and Group 5 (which contains PVP as a crystallisation inhibitor).
The results of the analysis of the proportion of eggs that hatched into larvae on Days 54 and 68 (following collections on Days 51 and 65, respectively) are presented in Table 2 below.
Table 2: Analysis of Proportion of Eggs that Hatch into Larvae Study Treatment No, of Proportion Percent PA/MI..1W
day z Group Dogs Hatched' Red action6 54 1 8 0.60 (4801800) NA' 54 2 a 0.05 (31/660) 92,2 <,001 54 5 i 8 0 02 (18/800) 96_3 1 <,001 68 1 g a64 (509/800) NA
68 3 5 0,12 (40/321) 80,4 <,001 0.03 (15/544) 95.6 <.001 1The proportion of eggs that hatched into larvae in the treated groups were compared with the proportion in the Untreated Control group;
2Day that egg hatch was counted; eggs were collected on Days 51 and 65, respectively, 48 hours after infestation;
4The proportion of eggs that hatched into larvae. The actual number that hatched into larvae over the total number of eggs incubated are listed in the parentheses;
5Percent reduction= [(C-T)/C]xl 00, where T and Care the proportion of eggs that hatched into larvae for the indicated treated group and the Untreated Control group, respectively;
6(Two-sided) probability value testing the hypothesis that the population proportion of the indicated treated group was not equal to the population proportion of the Untreated Control group;
'Percent reduction with respect to itself.
Eggs were collected from the groups Untreated Control, FRONTLINE Plus, and Treatment Group 5 on Day 54. Following incubation, the proportion of eggs that hatched in the two treated groups was compared with the Untreated Control group. The percent reduction of eggs that hatched into larvae was 92.2% and 96.3% for FRONTLINE
Plus and Treatment Group 5, respectively. For both, the population means of the treated and Untreated Control groups were significantly different (p < 0.001 for both; see Table 2).
Eggs were collected from the groups Untreated Control, Treatment Group 3 and Treatment Group 4 on Day 65. Following incubation, the proportion of eggs that hatched in the two treated groups was compared with the Untreated Control group. The percent reduction of eggs that hatched into larvae was 80.4% and 95.6% for Treatment Groups 3 and Treatment Group 4, respectively.
For both, the population means of the treated and Untreated Control groups were significantly different (p < 0.001 for both).
Conclusion In conclusion, all four fipronil:(S)-methoprene formulations provided excellent efficacy against adult flea infestations on dogs and prevented flea egg eclosion for several weeks past the single treatment. All formulations provided flea adulticide activity of 90% for at least 35 days and one formulation was highly effective up through 65 days.
Moreover, the formulations used in Treatment Group 4 (NM P alone) and Group 3 (DGME alone) were particularly effective.
The results show that fipronil and (S)-methoprene can be formulated in a variety of solvents and excipients and provide excellent activity for several weeks against adult fleas and in the prevention of flea egg eclosion.
The invention is further described with reference to the following numbered paragraphs.
1. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
2. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain ethanol, methanol or isopropanol.
3. A topical formulation according to paragraph 1 or paragraph 2 which does not contain a crystallisation inhibitor.
4. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain a crystallisation inhibitor.
5. A topical formulation according to paragraph 3 or paragraph 4 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
6. A topical formulation according to paragraph 4 or paragraph 5 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C
and a dielectric constant of between 10 and 40.
7. A topical formulation according to paragraph 4 or paragraph 5 wherein said formulation does not contain ethanol, methanol or isopropanol.
8. A topical formulation according to any preceding paragraph wherein the IGR is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyI)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
9. A topical formulation according to any preceding paragraph wherein the IGR is methoprene.
10. A topical formulation according to any one of paragraphs 1 to 8 wherein the IGR is pyriproxyfen.
11. A topical formulation comprising:
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
12. A topical formulation consisting essentially of:
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
13. A topical formulation consisting of:
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
14. A topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
15. A topical formulation consisting essentially of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants;
(iv) optionally one or more additional active agents; and (v) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants;
(iv) optionally one or more additional active agents; and (v) an organic solvent which is an optionally substituted pyrrolidone.
16. A topical formulation consisting of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants;
(iv) optionally one or more additional active agents; and (v) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants;
(iv) optionally one or more additional active agents; and (v) an organic solvent which is an optionally substituted pyrrolidone.
17. A topical formulation according to any preceding paragraph wherein the optionally substituted pyrrolidone is selected from 2-pyrrolidone, a 1-(C2_20-alkyl)-2-pyrrolidone, a 1-(C2_10-alkenyI)-2-pyrrolidone, a 1-(C38-cycloalkyl)-2-pyrrolidone, a 1-(Ci_6-hydroxyalkyl)-2-pyrrolidone, a 1-(C1_6-alkoxy-C1_6a1ky1)-2-pyrrolidone and 1-benzylpyrrolidone.
18. A topical formulation according to any preceding paragraph wherein the optionally substituted pyrrolidone is selected 1-methylpyrrolidone (NM P), 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s-butyl)-pyrrolidone, 1-(t-butyl)-pyrrolidone, 1-(n-butyI)-pyrrolidone, 1-hexylpyrrolidone, 1-viny1-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-(3-hydroxypropyI)-pyrrolidone, 1-(2-methoxyethyl)-pyrrolidone, 1-(3-methoxpropyI)-pyrrolidone and 1-benzylpyrrolidone, and mixtures thereof.
19. A topical formulation according to any preceding paragraph wherein the optionally substituted pyrrolidone is N-methylpyrrolidone (NMP).
20. A topical formulation according to any preceding paragraph wherein the fipronil is present in an amount of from about 1 to about 20 % (w/v).
21. A topical formulation according to paragraph 20 wherein the fipronil is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
22. A topical formulation according to any one of paragraphs 1 to 10 wherein the IGR
is present in an amount of from about 1 to about 20 % (w/v).
is present in an amount of from about 1 to about 20 % (w/v).
23. A topical formulation according to paragraph 22 wherein the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
24. A topical formulation according to any one of paragraphs 11 to 13 wherein the methoprene is present in an amount of from about 1 to about 20 % (w/v).
25. A topical formulation according to paragraph 24 wherein the methoprene is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
26. A topical formulation according any one of paragraphs 14 to 16 wherein the pyriproxyfen is present in an amount of from about 1 to about 20 % (w/v).
27. A topical formulation according to paragraph 26 wherein the pyriproxyfen is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
28. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
29. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
30. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
31. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
32. A topical formulation comprising:
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
33. A topical formulation comprising:
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain ethanol, methanol or isopropanol.
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain ethanol, methanol or isopropanol.
34. A topical formulation according to paragraph 32 or paragraph 33 which does not contain a crystallisation inhibitor.
35. A topical formulation comprising:
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether;
wherein said formulation does not contain a crystallisation inhibitor.
(i) fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether;
wherein said formulation does not contain a crystallisation inhibitor.
36. A topical formulation according to paragraph 34 or paragraph 35 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
37. A topical formulation according to paragraph 35 or paragraph 36 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C
and a dielectric constant of between 10 and 40.
and a dielectric constant of between 10 and 40.
38. A topical formulation according to paragraph 35 or paragraph 36 wherein said formulation does not contain ethanol, methanol or isopropanol.
39. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
40. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain ethanol, methanol or isopropanol.
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain ethanol, methanol or isopropanol.
41. A topical formulation according to paragraph 39 or paragraph 40 which does not contain a crystallisation inhibitor.
42. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain a crystallisation inhibitor.
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain a crystallisation inhibitor.
43. A topical formulation according to paragraph 41 or paragraph 42 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
44. A topical formulation according to paragraph 42 or paragraph 43 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C
and a dielectric constant of between 10 and 40.
and a dielectric constant of between 10 and 40.
45. A topical formulation according to paragraph 42 or paragraph 43 wherein said formulation does not contain ethanol, methanol or isopropanol.
46. A topical formulation according to any one of paragraphs 32 to 45 wherein the IGR
is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropy1)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyI)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropy1)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
47. A topical formulation according to paragraph 46 wherein the IGR is methoprene.
48. A topical formulation according to paragraph 46 wherein the IGR is pyriproxyfen.
49. A topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40.
50. A topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain ethanol, methanol or isopropanol.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain ethanol, methanol or isopropanol.
51. A topical formulation according to paragraph 49 or paragraph 50 which does not contain a crystallisation inhibitor.
52. A topical formulation comprising:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether;
wherein said formulation does not contain a crystallisation inhibitor.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether;
wherein said formulation does not contain a crystallisation inhibitor.
53. A topical formulation according to paragraph 51 or paragraph 52 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R" wherein the radicals R', R" and R" are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
54. A topical formulation according to paragraph 52 or paragraph 53 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C
and a dielectric constant of between 10 and 40.
and a dielectric constant of between 10 and 40.
55. A topical formulation according to paragraph 52 or paragraph 53 wherein said formulation does not contain ethanol, methanol or isopropanol.
56. A topical formulation according to any one of paragraphs 39 to 55 wherein the fipronil is present in an amount of from about 1 to about 20 % (w/v).
57. A topical formulation according to paragraph 56 wherein the fipronil is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
58. A topical formulation according to any one of paragraphs 39 to 57 wherein the IGR
is present in an amount of from about 1 to about 20 % (w/v).
is present in an amount of from about 1 to about 20 % (w/v).
59. A topical formulation according to paragraph 58 wherein the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
60. A topical formulation according to claim 47 wherein the methoprene is present in an amount of from about 1 to about 20 % (w/v).
61. A topical formulation according to paragraph 60 wherein the methoprene is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v).
62. A topical formulation according to paragraph 60 wherein the methoprene is present in an amount of about 9 to about 11 % (w/v).
63. A topical formulation according any one of paragraphs 48 to 57 wherein the pyriproxyfen is present in an amount of from about 1 to about 20 % (w/v).
64. A topical formulation according to paragraph 63 wherein the pyriproxyfen is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
65. A topical formulation consisting essentially of:
(i) fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether.
(i) fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether.
66. A topical formulation consisting of:
(i) fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether.
(i) fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether.
67. A topical formulation consisting essentially of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iii) a veterinarily acceptable carrier which is a glycol ether.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iii) a veterinarily acceptable carrier which is a glycol ether.
68. A topical formulation consisting of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iii) a veterinarily acceptable carrier which is a glycol ether.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iii) a veterinarily acceptable carrier which is a glycol ether.
69. A topical formulation according to any one of claims 32 to 38 and 49 to 68 wherein the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monoethyl ether (DGME), diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
70. A topical formulation according to paragraph 69 wherein the glycol ether is diethylene glycol monoethyl ether (DGME).
71. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
72. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
73. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
74. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
75. A topical formulation according to any one of paragraphs 1 to 27 and 32 to 72 wherein the formulation comprises one or more antioxidants.
76. A topical formulation according to paragraph 75 wherein the total amount of antioxidant present is from about 0.005 to about 1% (w/v), more preferably from about 0.01 to about 0.05% (w/v).
77. A topical formulation according to paragraph 75 or paragraph 76 wherein the antioxidant is selected from butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate and sodium thiosulphate, and mixtures thereof.
78. A topical formulation according to any preceding paragraph which is a spot-on formulation.
79. A topical formulation according to any preceding paragraph which is prepared for a dose of from 0.1 to 40 mg/kg of fipronil and from 0.1 to 40 mg/kg of the IGR.
80. A topical formulation according to paragraph 79 which is prepared for a dose of from 1 to 20 mg/kg of fipronil and from 1 to 30 mg/kg of the IGR.
81. A topical formulation according to paragraph 79 which is prepared for a dose of from 2 to 10 mg/kg of fipronil and from 2 to 20 mg/kg of the IGR.
82. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
83. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
84. A topical formulation consisting essentially of:
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
85. A topical formulation consisting of:
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
86. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
87. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
88. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethylene glycol monoethylether (DGME).
89. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethylene glycol monoethylether (DGME).
90. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME).
91. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME).
92. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
93. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
94. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
95. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS N-methylpyrrolidone.
96. A topical formulation consisting essentially of:
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
97. A topical formulation consisting of:
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
98. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):Et0H 8:1.
99. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):Et0H 8:1.
100 A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):Et0H 8:1.
101. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):Et0H 8:1.
102. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
103. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
104. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
105. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1
106. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
107. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
108. A topical formulation consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
109. A topical formulation consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v) ;
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v) ;
about 5 % polyvinyl pyrrolidone (w/v);
about 5% (w/v) polysorbate 80;
about 0.025 % (w/v) BHA; and QS diethyleneglycol monoethylether (DGME):Et0H 8:1.
110. A topical formulation according to any preceding paragraph for use in treating or controlling an ectoparasite infestation on an animal.
111. A topical formulation for use according to paragraph 110 wherein the animal is a domestic animal.
112. A topical formulation for use according to paragraph 110 wherein the animal is a dog or a cat.
113. A topical formulation for use according to paragraph 110 wherein the ectoparasite is a flea.
114. A topical formulation for use according to paragraph 110 wherein the ectoparasite is a tick.
115. A method of treating or controlling an ectoparasite on an animal, said method comprising topically applying a topical composition according to any one of paragraphs 1 to 109 to said animal.
116. A method according to paragraph 115 wherein the animal is a domestic animal.
117. A method according to paragraph 115 wherein the animal is a dog or a cat.
118. A method according to paragraph 115 wherein the ectoparasite is a flea.
119. A method according to paragraph 115 wherein the ectoparasite is a tick.
120. A method according to paragraph 115 wherein the topical composition is applied to a localised area having a surface area of 10 cm3 or less.
121. A method according to claim 115 wherein the topical composition is applied to a localised area between the animal's shoulder blades.
122. A method according to paragraph 115 wherein the topical composition is applied at one or two points.
123. A topical formulation, use or method substantially as described herein.
Various modifications and variations of the described aspects of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes of carrying out the invention which are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.
Various modifications and variations of the described aspects of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes of carrying out the invention which are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.
Claims (84)
1. A topical formulation comprising:
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
(i) fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
2. A topical formulation according to claim 1 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40.
3. A topical formulation according to claim 1 wherein said formulation does not contain ethanol, methanol or isopropanol.
4. A topical formulation according to any one of claims 1 to 3 which does not contain a crystallisation inhibitor.
5. A topical formulation according to any one of claims 1 to 4 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
6. A topical formulation according to any preceding claim wherein the optionally substituted pyrrolidone is selected from 2-pyrrolidone, a 1-(C2-20-alkyl)-2-pyrrolidone, a 1-(C2-10-alkenyl)-2-pyrrolidone, a 1-(C3-8-cycloalkyl)-2-pyrrolidone, a 1-(C1-6-hydroxyalkyl)-2-pyrrolidone, a 1-(C1-6-alkoxy-C1-6alkyl)-2-pyrrolidone and 1-benzylpyrrolidone.
7. A topical formulation according to any preceding claim wherein the optionally substituted pyrrolidone is selected 1-methylpyrrolidone (NMP), 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s-butyI)-pyrrolidone, 1-(.tau.-butyl)-pyrrolidone, 1-(n-butyI)-pyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-(3-hydroxypropyI)-pyrrolidone, 1-(2-methoxyethyl)-pyrrolidone, 1-(3-methoxpropyI)-pyrrolidone and 1-benzylpyrrolidone, and mixtures thereof.
8. A topical formulation according to any preceding claim wherein the optionally substituted pyrrolidone is N-methylpyrrolidone (NMP).
9. A topical formulation according to any preceding claim wherein the fipronil is present in an amount of from about 1 to about 20 % (w/v).
10. A topical formulation according to claim 9 wherein the fipronil is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
11. A topical formulation according to any preceding claim wherein the IGR
is present in an amount of from about 1 to about 20 % (w/v).
is present in an amount of from about 1 to about 20 % (w/v).
12. A topical formulation according to claim 11 wherein the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
13. A topical formulation according to any preceding claim wherein the IGR
is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyl)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyl)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
14. A topical formulation according to any preceding claim wherein the IGR
is methoprene.
is methoprene.
15. A topical formulation according to any one of claims 1 to 14 which consists essentially of:
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
16. A topical formulation according to any one of claims 1 to 14 which consists of:
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
17. A topical formulation according to claim 1 which consists essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
18. A topical formulation according to claim 1 which consists of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS N-methylpyrrolidone.
19. A topical formulation according to any one of claims 1 to 13 wherein the IGR is pyriproxyfen.
20. A topical formulation according to claim 1 which consists essentially of:
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
21. A topical formulation according to claim 1 which consists of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is an optionally substituted pyrrolidone.
22. A topical formulation according to claim 1 which consists essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
23. A topical formulation according to claim 1 which consists of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS N-methylpyrrolidone.
24. A topical formulation which comprises:
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
fipronil;
(ii) methoprene;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
25. A topical formulation comprising:
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is an optionally substituted pyrrolidone.
26. A topical formulation comprising:
fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
fipronil in an amount of from about 10 to about 20 % w/v;
(ii) an IGR in an amount of from about 10 to about 20 % w/v;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100 C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
27. A topical formulation comprising:
fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
fipronil;
(ii) an IGR;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is a glycol ether selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
28. A topical formulation according to claim 26 or claim 27 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40.
29. A topical formulation according to claim 26 or claim 27 wherein said formulation does not contain ethanol, methanol or isopropanol.
30. A topical formulation according to any one of claims 26 to 29 which does not contain a crystallisation inhibitor.
31. A topical formulation according to any one of claims 26 to 30 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester, lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
32. A topical formulation according to any one of claims 27 to 31 wherein the IGR is present in an amount of from about 1 to about 20 % (w/v).
33. A topical formulation according to claim 32 wherein the IGR is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
34. A topical formulation according to any one of claims 26 to 33 wherein the IGR is selected from cyromazine, lufenuron, 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea, azadirachtin, diofenolan, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2-(2-chloro-2methylpropyl)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one.
35. A topical formulation according to claim 34 wherein the IGR is methoprene.
36. A topical formulation according to claim 26 consisting essentially of:
fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is a glycol ether.
fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is a glycol ether.
37. A topical formulation according to claim 26 consisting of:
fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is a glycol ether.
fipronil in an amount of about 10 to about 20 % w/v;
(ii) methoprene in an amount of about 10 to about 20 % w/v; and (iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iv) an organic solvent which is a glycol ether.
38. A topical formulation according to claim 27 wherein the IGR is methoprene, and the methoprene is present in an amount of from about 1 to about 20 % (w/v).
39. A topical formulation according to claim 38 wherein the methoprene is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
40. A topical formulation according to any one of claims 26 to 34 wherein the IGR is pyriproxyfen.
41. A topical formulation comprising:
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants; and (iv) an organic solvent which is glycol ether;
wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40; or wherein said formulation does not contain a crystallisation inhibitor.
42. A topical formulation according to claim 41 wherein said formulation does not contain an organic co-solvent having a boiling point of below 100°C and a dielectric constant of between 10 and 40.
43. A topical formulation according to claim 41 wherein said formulation does not contain ethanol, methanol or isopropanol.
44. A topical formulation according to any one of claims 41 to 43 wherein said formulation does not contain a crystallisation inhibitor.
45. A topical formulation according to any one of claims 41 to 44 wherein the crystallisation inhibitor is selected from:
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
- polyvinylpyrrolidone, a polyvinyl alcohol, a copolymer of vinyl acetate and vinylpyrrolidone, a polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, a polyoxyethylenated sorbitan ester; lecithin, sodium carboxymethylcellulose and an acrylic derivative;
- an anionic surfactant;
- a cationic surfactant;
- an amine salt of formula N+R'R'R"' wherein the radicals R', R" and R"' are each independently an optionally hydroxylated hydrocarbon radical;
- a nonionic surfactant; and - an amphoteric surfactant.
46 A topical formulation according to any claim 27 or claim 41 wherein the fipronil is present in an amount of from about 1 to about 20 % (w/v).
47. A topical formulation according to claim 46 wherein the fipronil is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 %
(w/v), even more preferably from about 9 to about 11 % (w/v).
(w/v), even more preferably from about 9 to about 11 % (w/v).
48. A topical formulation according to claim 27 or claim 41 wherein the pyriproxyfen is present in an amount of from about 1 to about 20 % (w/v).
49. A topical formulation according to claim 48 wherein the pyriproxyfen is present in an amount of from about 5 to about 15 % (w/v), more preferably from about 8 to about 12 % (w/v), even more preferably from about 9 to about 11 % (w/v).
50. A topical formulation according to claim 26 or claim 27 consisting essentially of:
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iii) a veterinarily acceptable carrier which is a glycol ether.
fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iii) a veterinarily acceptable carrier which is a glycol ether.
51. A topical formulation according to claim 26 or claim 27 consisting of:
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iii) a veterinarily acceptable carrier which is a glycol ether.
(i) fipronil;
(ii) pyriproxyfen;
(iii) optionally one or more antioxidants and/or one or more additional active agents;
and (iii) a veterinarily acceptable carrier which is a glycol ether.
52. A topical formulation according to any one of claims 26 and 28 to 51 wherein the glycol ether is selected from methyl diglycol, ethyl diglycol, propyl diglycol, butyl diglycol, methyl glycol, ethyl glycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, diethylene glycol monoethyl ether (DGME), diethylene glycol monobutyl ether, diethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, and mixtures thereof.
53. A topical formulation according to claim 52 wherein the glycol ether is diethylene glycol monoethyl ether (DGME).
54. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
55. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % (S)-methoprene (w/v); and QS diethylene glycol monoethylether (DGME).
56. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
57. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 10 % pyriproxyfen (w/v); and QS diethyleneglycol monoethylether (DGME).
58. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
59. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
60. A topical formulation according to claim 26 consisting essentially of:
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
61. A topical formulation according to claim 26 consisting of:
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 20 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
62. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
63. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME).
64. A topical formulation according to claim 26 consisting essentially of:
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
65. A topical formulation according to claim 26 consisting of:
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
about 5 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME).
66. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):EtOH 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):EtOH 8:1.
67. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):EtOH 8:1.
about 10 % fipronil (w/v);
about 5 % pyriproxyfen (w/v); and QS diethylene glycol monoethylether (DGME):EtOH 8:1.
68. A topical formulation according to claim 26 consisting essentially of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):EtOH 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):EtOH 8:1.
69. A topical formulation according to claim 26 consisting of:
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):EtOH 8:1.
about 10 % fipronil (w/v);
about 20 % (S)-methoprene (w/v);
QS diethylene glycol monoethylether (DGME):EtOH 8:1.
70. A topical formulation according to any one of claims 1 to 17, 18 to 22, 24 to 54, 56, 58, 60, 62, 64, 66 or 68 wherein the formulation comprises one or more antioxidants.
71. A topical formulation according to claim 70 wherein the total amount of antioxidant present is from about 0.005 to about 1% (w/v), more preferably from about 0.01 to about 0.05% (w/v).
72. A topical formulation according to claim 70 or claim 71 wherein the antioxidant is selected from butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate and sodium thiosulphate, and mixtures thereof.
73. A topical formulation according to any preceding claim which is a spot-on formulation.
74. A topical formulation according to any preceding claim which is prepared for a dose of from 0.1 to 40 mg/kg of fipronil and from 0.1 to 40 mg/kg of the IGR.
75. A topical formulation according to any preceding claim for use in treating or controlling an ectoparasite infestation on an animal.
76. A topical formulation for use according to claim 75 wherein the animal is a dog or a cat.
77. A topical formulation for use according to claim 75 wherein the ectoparasite is a flea or a tick.
78. A method of treating or controlling an ectoparasite on an animal, said method comprising topically applying a topical composition according to any one of claims 1 to 74 to said animal.
79. A method according to claim 78 wherein the animal is a dog or a cat.
80. A method according to claim 78 wherein the ectoparasite is a flea or a tick.
81. A method according to claim 78 wherein the topical composition is applied to a localised area having a surface area of 10 cm3 or less.
82. A method according to claim 81 wherein the topical composition is applied to a localised area between the animal's shoulder blades.
83. Use of a composition according to any one of claims 1 to 74 in the preparation of a medicament for treating or controlling an ectoparasite on an animal.
84. A topical formulation, use or method substantially as described herein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB15207244 | 2015-11-24 | ||
GBGB1520724.4A GB201520724D0 (en) | 2015-11-24 | 2015-11-24 | Veterinary formulations |
PCT/US2016/062364 WO2017091417A1 (en) | 2015-11-24 | 2016-11-16 | Veterinary formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3006073A1 true CA3006073A1 (en) | 2017-06-01 |
CA3006073C CA3006073C (en) | 2021-01-12 |
Family
ID=55133293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3006073A Active CA3006073C (en) | 2015-11-24 | 2016-11-16 | Topical veterinary formulations comprising fipronil and methoprene |
Country Status (8)
Country | Link |
---|---|
US (1) | US10898467B2 (en) |
EP (1) | EP3379928A1 (en) |
JP (1) | JP6966440B2 (en) |
AU (1) | AU2016361304B2 (en) |
CA (1) | CA3006073C (en) |
GB (1) | GB201520724D0 (en) |
MX (1) | MX2018006350A (en) |
WO (1) | WO2017091417A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019239358A1 (en) * | 2018-06-13 | 2019-12-19 | Adama Makhteshim Ltd. | Agricultural composition |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8531485D0 (en) | 1985-12-20 | 1986-02-05 | May & Baker Ltd | Compositions of matter |
GB9120641D0 (en) | 1991-09-27 | 1991-11-06 | Ici Plc | Heterocyclic compounds |
GB9306184D0 (en) | 1993-03-25 | 1993-05-19 | Zeneca Ltd | Heteroaromatic compounds |
IE80657B1 (en) * | 1996-03-29 | 1998-11-04 | Merial Sas | Insecticidal combination to control mammal fleas in particular fleas on cats and dogs |
DE102006061538A1 (en) | 2006-12-27 | 2008-07-03 | Bayer Healthcare Ag | Agent for controlling parasites on animals comprises an N-phenylpyrazole, a pyrethroid, an aliphatic cyclic carbonate and an aliphatic polyether |
DE102006061537A1 (en) | 2006-12-27 | 2008-07-03 | Bayer Healthcare Ag | Agent for controlling parasites on animals comprises an N-phenylpyrazole, an aliphatic cyclic carbonate and an aliphatic polyether |
TW200924647A (en) | 2007-08-30 | 2009-06-16 | Schering Plough Ltd | Local topical administration formulations containing fipronil |
US9433615B2 (en) * | 2007-09-06 | 2016-09-06 | The Hartz Mountain Corporation | Animal parasite-control method using insect growth regulators |
FR2925337B1 (en) | 2007-12-21 | 2010-01-15 | Virbac | PHARMACEUTICAL COMPOSITION CONTAINING AN N-PHENYLPYRAZOLE DERIVATIVE AND GLYCOFUROL, USE FOR THE PREPARATION OF A TOPICAL VETERINARY DRUG FOR CONTROLLING CHIPS |
GB2457734A (en) | 2008-02-25 | 2009-08-26 | Norbrook Lab Ltd | Topical phenyl pyrazole insecticide composition |
GB2464449B (en) * | 2008-09-05 | 2011-10-12 | Norbrook Lab Ltd | A topical ectoparasticide composition |
KR20120032459A (en) * | 2009-02-16 | 2012-04-05 | 시플라 리미티드 | Topical composition |
AU2010224685A1 (en) | 2009-03-18 | 2011-11-03 | Fidopharm, Inc. | Parasiticidal formulation |
GB0905365D0 (en) * | 2009-03-27 | 2009-05-13 | Norbrook Lab Ltd | A topical parasiticide composition |
US8614244B2 (en) * | 2009-09-22 | 2013-12-24 | Segeant's Pet Care Products, Inc. | Spot-on pesticide composition |
JP5736376B2 (en) * | 2009-09-22 | 2015-06-17 | サージェンツ ペット ケア プロダクツ アイエヌシー. | Topical insecticidal composition |
UA108641C2 (en) * | 2010-04-02 | 2015-05-25 | PARASITICID COMPOSITION CONTAINING FOUR ACTIVE AGENTS AND METHOD OF APPLICATION | |
US20130261161A1 (en) * | 2011-09-30 | 2013-10-03 | Velcera, Inc. | Antiparasitic formulations |
JO3626B1 (en) * | 2012-02-23 | 2020-08-27 | Merial Inc | Topical compositions comprising fipronil and permethrin and methods of use |
CN103355324A (en) * | 2013-06-29 | 2013-10-23 | 海利尔药业集团股份有限公司 | Insecticidal composition containing fipronil and pyriproxyfen |
EP3211998B1 (en) * | 2014-10-31 | 2021-04-07 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal composition comprising fipronil |
-
2015
- 2015-11-24 GB GBGB1520724.4A patent/GB201520724D0/en not_active Ceased
-
2016
- 2016-11-16 MX MX2018006350A patent/MX2018006350A/en unknown
- 2016-11-16 CA CA3006073A patent/CA3006073C/en active Active
- 2016-11-16 JP JP2018526875A patent/JP6966440B2/en active Active
- 2016-11-16 EP EP16806371.7A patent/EP3379928A1/en active Pending
- 2016-11-16 WO PCT/US2016/062364 patent/WO2017091417A1/en active Application Filing
- 2016-11-16 US US15/777,886 patent/US10898467B2/en active Active
- 2016-11-16 AU AU2016361304A patent/AU2016361304B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019502665A (en) | 2019-01-31 |
AU2016361304B2 (en) | 2021-11-25 |
CA3006073C (en) | 2021-01-12 |
US20180344697A1 (en) | 2018-12-06 |
NZ743289A (en) | 2023-12-22 |
GB201520724D0 (en) | 2016-01-06 |
JP6966440B2 (en) | 2021-11-17 |
EP3379928A1 (en) | 2018-10-03 |
MX2018006350A (en) | 2018-09-18 |
WO2017091417A1 (en) | 2017-06-01 |
AU2016361304A1 (en) | 2018-06-28 |
US10898467B2 (en) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018202648B2 (en) | Topical compositions comprising fipronil and permethrin and methods of use | |
EA038853B1 (en) | Pesticidal compositions comprising an isoxazoline active agent and methods of use thereof | |
EP1887866A1 (en) | Spot-on formulations for combating parasites | |
AU2015339096B2 (en) | Parasiticidal composition comprising fipronil | |
CA3006073C (en) | Topical veterinary formulations comprising fipronil and methoprene | |
CN117986154A (en) | Antiparasitic compounds | |
OA17083A (en) | Topical compositions comprising fipronil and permethrin and methods of use. | |
OA16809A (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20180523 |